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ABSTRACT
Dendritic cell-mediated cancer immunotherapy employs several ways to engage
tumor antigens. We have demonstrated both in pre-clinical animal studies and early
clinical trials that dendritomas, highly purified hybrids between dendritic cells and tumor
cells, are superior activators of anti-tumor immunity. In the present study, we examined
the expression profile of several inflammatory chemokine and chemokine receptors of
dendritomas by RNA microarray and real-time RT-PCR. The results indicate that
dendritomas made from immature DCs and tumor cells express higher levels of CCL3,
CCL5, and CCL22 and lower levels of CCR2 and CCR5, which mimics LPS matured
DCs, while dendritomas made from mature DCs and tumor cells show a reversed
expression profile of these genes: decreased levels of CCLs and increased levels of
CCRs. Our data support the notion that dendritomas made from immature DCs and tumor
cells may be more effective in migration from the injection site to draining lymph nodes
and therefore make them more effective in stimulating anti-tumor immunity.
Morinda citrifolia (Noni) has been used as a folk remedy to treat a myriad of
ailments, and is gaining in popularity as a modern dietary supplement to enhance the
immune system. Recent studies have shown that Noni juice has anticancer activity.
Studies from our lab demonstrated that fermented Noni juice not only prevents mouse
sarcoma tumor development but also eradicates existing tumors. Fermented Noni can also
directly engage dendritic cells with B cells. Since Noni contains a wide array of
microorganisms, and upon fermentation, all but one are killed, it is presumed to contain a
plethora of degraded microbial products that would serve as microbial stress signals. We
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hypothesized that Noni may activate dendritic cells by engaging their toll-like receptors
(TLRs), and investigated genes associated with TLR signaling via real-time RT-PCR. It
was determined that Noni stimulates early low levels of inflammatory cytokines,
followed by a latent upregulation of anti-inflammatory mediators. Intriguingly, Noni also
appeared to trans-differentiate dendritic cells toward macrophage-like cells.
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1. LITERATURE REVIEW
1.1. The Immune System and Cancer
In 1909 Paul Ehrlich first hypothesized our immune systems are capable of
destroying initial emerging tumor cells (Ehrlich, 1909); however, research in this area
had to await the developing field of immunology. Nearly half a century later, Burnett
and Thomas separately rebirthed the concept, eventually entitling it
‘immunosurveillance’ (Burnet, 1957) (Thomas, 1959). Experiments furiously followed
aimed at supporting this ideology; however in the late 1970s immunosurveillance was
abandoned due to limited understanding of nude mice at the time, and their inability to
acquire higher amounts of spontaneous tumor formation (Dunn et al., 2002). It is now
acknowledged that nude mice have traceable amounts of αβ T cells as well as NK cells
and other innate effectors. Although several attempts were made to revive the
immunosurveillance concept, it wasn’t until the mid to late 1990s that this area was fully
rejuvenated. At that point it was further defined as ‘immunoediting’ in 2002 to more
accurately describe the intricate balance between host defense against tumor formation
(elimination) and tumor immune evasion (escape) (Dunn et al., 2003).
Immunoediting is described as a three-pronged process including elimination,
equilibrium and escape (Dunn, 2003) as shown in Figure 1.1. The first phase implies
aberrant cells are constantly being transformed in a healthy host, and the immune system
duly recognizes and eliminates these cells, hence the title ‘elimination’. The second step
requires the collection of several genetic modifications and a Darwinian-like selection of
tumor cells that have lost their immunogenicity; however, these cells are kept in check by

1

innate immune cells and T cells, which amounts to a state of equilibrium. The selection
of tumor cells that have lost immunogenicity can have detrimental effects. It is these
cells that are capable of escaping immune detection and have the potential to acquire all
seven hallmarks of cancer. These hallmarks include: (1) self-sufficient, perpetuated
growth signals, (2) alluding anti-growth signals, (3) inflammation, (4) uncontrolled
replication, (5) evading apoptosis, (6) angiogenesis, and (7) metastasis (Colatta et al.,
2009; Montavi, 2009; Hanahan et al., 2000). The successful treatment of cancer lies in
the understanding of how the body initially recognizes and destroys tumor cells as well as
how the immune system is commandeered for their protection and proliferation. To
eliminate cancer we must tip the scales back toward tumor elimination and minimize the
factors allowing for its immune escape.
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(Dunn et al., 2003. Ann Rev Immunol. 22: 329-360)

Figure 1.1. The three Es of cancer immunoediting. Cancer immunoediting
encompasses three processes. (a) Elimination corresponds to immunosurveillance. (b)
Equilibrium represents the process by which the immune system iteratively selects and/or
promotes the generation of tumor cell variants with increasing capacities to survive
immune attack. (c) Escape is the process wherein the immunologically sculpted tumor
expands in an uncontrolled manner in the immunocompetent host. In (a) and (b),
developing tumor cells (blue), tumor cell variants (red) and underlying stroma and
nontransformed cells (gray) are shown; in (c), additional tumor variants (orange) that
have formed as a result of the equilibrium process are shown. Different lymphocyte
populations are as marked. The small orange circles represent cytokines and the white
flashes represent cytotoxic activity of lymphocytes against tumor cells.
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1.2. Cancer Immunotherapy
Cancer immunotherapy hinges on the idea that we can manipulate the body’s
immune milieu to favor tumor rejection. This idea has developed into one of the most
complex areas of cancer research. With countless immune mediators like cytokines,
growth factors and ‘danger signals’ (pattern-recognition receptor ligands), along with
inimitable tumor cell profiles and microenviroments, it is impossible to identify one
method of treatment effective for all cancer patients; hence the strong desire to advance
the field of personalized cancer therapies (Hayden et al., 2009). Several different types
of immunotherapy are currently being studied for cancer treatment, including monoclonal
antibody therapy, radioimmunotherapy, and cell-based therapies (adoptive transfer of T
cells and dendritic cell-based immunotherapy). In 1997, Rituximab was the first
monoclonal antibody approved by the FDA and it opened the door for cancer
immunotherapies (Biotechnology Law Report, 1998). Several more monoclonal
antibodies were approved shortly after, and the first radioactive-labeled antibody was
approved in 2002, Zevalin (Schilder, 2002). The first vaccine for cancer prevention,
Gardasil, was approved by the FDA in 2006 (Zawisza, 2006). It is an immunization
against certain HPVs that are associated with increased cervical cancer risk, and is the
first drug specifically targeting inflammation-induced cancers. There are, however, no
FDA approved cell-based therapeutic cancer vaccines. Here we will further examine
dendritic cell-based therapies.
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1.3. Dendritic Cells
DCs were first discovered in 1868 in the epidermis by Paul Langerhans, thus
termed ‘Langerhans cells’ (Langerhans, 1868). But it was more than a century before
they were identified in other tissues and termed ‘dendritic cells’ by Steinman and Cohn in
1973 (Steinman et al., 1973). Their scarcity proved them difficult to isolate and study.
Consequently, it wasn’t until the early 1990s when DC purification improved and the first
clinical trial for DC vaccines, published in 1995, showed promising results (Mukherji et
al., 1995). DCs are professional antigen-presenting cells poised to bridge innate and
adaptive immunity while directing the balance of immunity and tolerance. Their crosstalk with natural killer (NK) cells (Fernandez et al., 1999), NKT cells (Fujii et al., 2002)
and γδT cells (Conti et al., 2005) hastens innate immunity, while synchronistically
presenting antigen to lymphocytes calling for acquired protection. There is no other cell
quite as capable of building this union. Because of this unique property, many
immunologists aim to harness the power of the dendritic cell for therapies from cancer
treatment and prevention to reversal of type 1 diabetes (Giannoukakis et al., 2006) and
AIDS vaccinations (Rinaldo et al., 2009). Here we will focus on dendritic cell
involvement with cancer. The dendritic cell is instrumental in deciphering whether the
immune system will eliminate tumor cells or tolerate their existence eventually leading to
immune escape and malignant progression. What determines this balance? What factors
influence the pivotal decision by the dendritic cell? How can we harness their properties
and utilize them against the very disease they are protecting? The next decade of
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dendritic cell-based cancer research will, with anticipation, unravel some of these
mysteries.
1.4. Dendritic Cells and Cancer
It has been established that the eradication of cancer cells requires both innate and
adaptive immunity (Chaudhuri et al., 2009; Diefenbach et al., 2002), as well as activation
of CD4+ and CD8+ T cells. DCs are one of the primary cells capable of helping or
hindering this process. Once tumor cells have effectively escaped immune recognition,
the tumor microenvironment favors tolerance, and the surrounding and infiltrating
immune cells are often usurped for the tumors advantage. Indeed, dendritic cells from
cancer patients are functionally compromised (Pinzon-Charry et al., 2005; Shurin et al.,
2006). Often these DCs are inhibited in differentiation and maturation (Almand et al.,
2000), which could be due to the over-expression of STAT3 by tumor cells and
subsequent upregulation of STAT3 by DCs, thus reducing their expression of costimulatory and MHC class II molecules, or by the active recruitment of immature DCs to
tumor tissues by way of tumor-produced chemokines (Bell et al., 1999). It has been
shown that most tumors have higher numbers of DC infiltrates than surrounding healthy
tissues (Almand et al., 2000), so it would be advantageous to develop a treatment aimed
at reprogramming the capability of DCs to recognize tumor cells as diseased cells, then
process and present tumor antigen to surrounding innate and adaptive effector cells,
under an immune stimulating environment.
The most researched immune cells with tumoricidal properties are NK cells and
cytotoxic T lymphocytes (CTLs). NK cells recognize tumor cells via downregulation of
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MHC class I molecules (in the presence of other activating signals) (Bubenik et al., 2004)
and upregulation of stress-induced NKG2D ligands (Raulet et al., 2009). Although NK
cells are capable of direct tumor killing, DCs are involved in cross-talk with NK cells,
which enhances NK cytotoxicity (Terme et al., 2008). Although CD4+ T helper cells are
now receiving more attention, cytotoxic T lymphocytes (CTLs) are the most researched
cell in the adaptive immune branch accountable for anti-tumor responses. DCs present
antigen to CD8+ T cells via the endogenous pathway, or in the case of tumor antigens, by
way of cross-presentation. Based on in vitro experiments, there are seven defined modes
of cross-presenting tumor antigens to T-cells (Melief, 2008). Transfer of antigens may
occur by 1) phagocytosing antigens from necrotic or apoptotic tumor cells, 2)
phagocytosing soluble antigens bound to heat shock proteins or other chaperonins, 3)
ingestion of soluble proteins secreted from tumor cells, 4) uptake of exosomes secreted
by tumor cells, 5) transfer of protein fragments through gap junctions, 6) direct nibbling
of tumor cell plasma-membrane by DCs, and 7) ‘cross-dressing’, where dead tumor cells
transfer MHC-I:peptide complexes directly to DCs. Regardless of the method of crosspresentation, if DCs are not properly stimulated, the resulting presentation of antigen to
either CD4+ or CD8+ T cells induces tolerance via deletion or regulatory T cell
stimulation (Melief, 2008). It was demonstrated that both DCs and NK cells, after crosstalk, were more effective at inducing Th1 and CTL responses in both human in vitro and
in vivo mouse studies (Kalinski et al., 2005). Thus, DCs play a vital role in recruiting
innate and adaptive tumor-killing cells.
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1.4.1. Dendritic Cell Vaccines
Dendritic cells used for cancer vaccines have been researched since the mid
1990’s. The first whole-tumor cell DC vaccine clinical trial used autologous DCs pulsed
ex vivo with the patient’s own tumor antigens and administered subcutaneously (Hsu et
al., 1996). This first trial treated four patients with B-cell lymphoma and was largely
successful. All four patients had measurable antitumor cellular immune responses and
three patients had positive clinical responses. As clinical trials began for other types of
DC cancer vaccines, there were less encouraging results. Broad spectrum statistics of the
outcome of all DC vaccine clinical trials yielded an overall clinical response of about 7%;
however, other cancer vaccines not utilizing DCs (tumor cell-only, peptide-only or viral
based vaccines) have only about a 3.5% response rate (Rosenberg et al., 2004). To
optimize the DC cancer vaccine, researchers have examined antigen loading strategies,
maturation of DCs, and route of administration.
1.4.2. Antigen Loading Strategies
Dendritic cell antigen loading strategies can be broken into three basic categories:
RNA or DNA, peptide or protein, and whole tumor loading. Nucleic acid loading of DCs
is capable of utilizing the entire repertoire of tumor antigens, if total RNA is extracted
from tumor cells (Kalady et al., 2004). This method has the unique advantage of
avoiding unwanted autoimmune reactions by subtractive hybridization with healthy cell
mRNA (Boczkowski et al., 1996). Also, it is a promising therapy for patients without
identified tumor-associated antigens (TAAs) or that lack sufficient tumor tissues to
qualify for whole-tumor cell vaccine approaches. Several drawbacks to this method
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include immunodominance, where viral vector antigens dampen the response to the
tumor antigens; CTL targeting of the transfected DC eliminating these cells before
eliciting the desired antitumor response; and a limited number of repeated vaccinations
due to the anti-viral response (Mitchell et al., 2000) (Terando et al., 2007).
Since most tumor antigens are actually self-derived, they are typically considered
weak antigens; therefore, with the discovery of TAAs (Lewis et al., 2003) many
researchers began to pulse DCs with synthetic peptide antigens such as Her-2/neu,
MAGE-1, CEA and many other TAAs (Disis et al., 1999; Hu et al., 1996; Morse et al.,
1999; Nair et al., 1999). The upside to TAA-pulsed DC cancer vaccines is that these
peptides could be synthetically manufactured, eliminating the need for patient tumor
samples, and it reduces the possibility of autoimmune induction. This technique is
limited quite heavily, however, with the requirement of tumor immunogenic epitope
identification and HLA-typing, and it only activates cellular immunity. Some evidence
has been given, however, to suggest that immunity against tumor cells not carrying the
particular TAA is possible (Disis et al., 1999; Bellone et al., 1997). To circumvent the
need for defined peptide epitopes and MHC restriction, DCs have also been loaded with
soluble recombinant or purified tumor proteins (Nonn et al., 2003; Shojaeian et al.,
2009). These proteins are ingested by DCs via macropinocytosis with simple co-culture
of DCs and proteins, and although they are primarily presented via MHC class I, they are
not restricted to a single MHC class (Svane et al., 2003). Overall, peptide and protein
pulsing of DCs limits the pulsing antigen to defined TAAs. Unless a potent immune
attack follows, immunosculpting may occur to delete tumor cells with the defined TAAs,
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but leave behind malignant cells not expressing these antigens, allowing for tumor escape
once again. Because of this, many scientists have pursued whole-tumor antigen
strategies.
It seems whole-tumor antigen pulsing of DCs would present many self-antigens
that would interfere with potent antitumor immune responses, however clinical responses
of whole-tumor cell DC vaccines are comparable to peptide, protein and nucleic acid
pulsed DCs (Terando et al., 2007; Koido et al., 2007). Whole-tumor antigen DC
vaccines are capable of processing and presenting a wide array of tumor antigens, both
known and unknown, to effector T cells, NK cells and other tumoricidal immune cells.
This approach appears to have an advantage over the other methods of DC loading since
it has the capacity to activate a much larger population of lymphocytes. Within the field
of whole-tumor antigen pulsed DC cancer vaccines, there are two main methods of
deriving these antigens. DCs can be pulsed with whole-cell tumor lysates (apoptotic or
necrotic cells) or DCs can be fused to tumor cells. There is evidence that DCs are more
capable of antigen uptake, processing and presentation from necrotic tumor cells, rather
than apoptotic cells (Scheffer et al., 2003; Sauter et al., 2000). Contrary to this
observation, apoptotic tumor cells elicited a much stronger antitumor T cell response than
necrotic cells (Scheffer et al., 2003). This dichotomy could be due to improper methods
of ‘necrosing’ tumor cells. In the body, necrotic tumor cells are in a hypoxic and stressinducing environment, which would increase the expression of stress signals that
augment DC activation. Most methodologies for preparing necrotic tumor cells ex vivo
employ the freeze/thaw method. This method has recently been shown to diverge from
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natural necroses in that the cells become necrotic in the absence of stress (Hatfield et al.,
2008). The lack of stress signals from the cells may dampen their immunogenicity.
Indeed, it was observed that freeze/thaw lysates were not capable of proper costimulatory
molecule and MHC class II induction and suppressed Toll-like receptor maturation of
DCs (Hatfield et al., 2008). The obvious drawback for this method of antigen loading (as
well as total tumor RNA transfection of DCs) is the potential to incite autoimmunity;
however, clinical trials to date have not observed detectable autoimmune reactions (Zhou
et al., 2009; Homma et al., 2006). Also, there must be a sufficient amount of tumor
tissue available for this therapy, limiting it to patients with solid tumors large enough for
surgical removal and subsequent ex vivo cell culture.
There have been numerous attempts to define whether tumor cell lysate pulsing or
DC-tumor cell fusions are superior. So far there is more supporting evidence for the
efficacy of DC-tumor cell fusions rather than lysate-pulsed DC vaccines (Galea-Lauri et
al., 2004; Shimizu et al., 2004; Kao et al., 2005); however, the rationale behind this has
not yet been determined. It is possible that the act of fusion induces enough of a stress
response in DCs that enhances their immunogenicity. Dendritic cell-tumor cell fusions
have received much attention for DC-based cancer vaccines since they are capable of
presenting the entire array of tumor antigens, both known and unknown, to T cells via
MHC class I and II molecules. There are two methods for creating DC-tumor
hybridomas: electrofusion and chemical fusion with polyethylene glycol (PEG).
Electrofusion represents a better choice for designing DC fusion vaccines since there is
more control over the process and it gives more consistent fusion rates from day-to-day

11

and between users than PEG-fusion. PEG fusion tends to be highly unpredictable, giving
rise to varying fusion rates critically dependent on constant temperature, precise
administration and different administrators. PEG fusion would greatly benefit from an
automated system. Regardless of the method of creating DC-tumor fusions, these cells
integrate their cytoplasm, but have separate nuclei, allowing for both cells to be partially
functional and produce TAAs from the tumor cell which can be complexed with DCderived MHC molecules (Koido et al., 2004). Several studies have used allogeneic DCs
fused with autologous tumor cells with promising results (Zhou et al., 2009; Lei et al,
2009); however, one of the clear disadvantages of using allogeneic DCs is the limitation
of eliciting only CD8+ T cell responses. It is becoming more widely acknowledged that
CD4+ T cells are necessary for the ultimate antitumor response (Marzo et al., 2000;
Tanaka et al., 2005). New methods of combining DC-tumor fusions with adjuvants, such
as OK-432 (Koido et al., 2007) and HSP70 (Karyampudi et al., 2008), or inhibiting T
regulatory cells (Li et al., 2007) suggest even more effective strategies for DC cancer
vaccines.
1.4.3. Maturation State of Dendritic Cells for Fusion Vaccines
The maturation state of DCs for cancer vaccines has been an area of intense
scrutiny over the last several years. In general, immature dendritic cells are more
effective at antigen uptake (Rovere et al., 1998) and mature dendritic cells are capable of
presenting these antigens to effector cells and eliciting stronger immunologic responses
(Guermonprez et al., 2002). In fact, the presentation of antigens by immature dendritic
cells often skews the immune response toward tolerance (Steinman et al., 2003). So,
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presumably, immature DCs would be most effective to utilize when pulsing or fusing
with antigen; however, the vaccine end product should consist of properly matured
dendritic. This clear distinction is not as defined in animal and clinical settings, however.
Indeed, immature DCs were demonstrated to induce potent cytolytic activity by
splenocytes, when fused with MC38 tumor cells (Takeda et al., 2003). And other
experiments have shown no attributing difference between the effectiveness of immature
or mature DC-tumor fusions (Vasir et al., 2008), while others clearly argue the necessity
of mature DCs for vaccine therapy (Baggers et al., 2000). Although general upregulation
of CD80, CD86, CD83, CD40 and MHC class II molecules correspond with a maturing
DC phenotype, the necessary profile of these proteins and the extent to which they must
be expressed for maximum efficacy has not yet been fully elucidated. Thus, the plasticity
of DCs has been a complicating factor in designing optimal DC vaccines.
1.5. Dendritic Cells and Chemokines
Chemokines are small chemotactic cytokines that direct the trafficking of immune
cells, regulate angiogenesis/angiostasis, and can be involved in the promotion of
metastasis. Here we will focus on their chemotactic effect on immune cells, specifically
dendritic cells. During an infection or inflammatory response, inflammatory chemokines
are rapidly produced (CCL2, CCL4, CCL5, CXCL8) (Sallusto et al., 1999). Circulating
immature DCs express inflammatory chemokine receptors (CXCR1, CCR1, CCR2,
CCR5) (Allavena et al., 2000), which allow recruitment to sites of inflammation to take
up antigen and aid the immune response against infection. As shown in Figure 1.2, when
DCs reach these sites of inflammation and are exposed to maturation stimuli (CD40L,
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PRR ligands, inflammatory cytokines), they undergo maturation, decreasing their antigen
capturing abilities and increasing MHC class I and II and costimulatory molecules, with a
concomitant decrease in inflammatory chemokine receptor expression (Dieu et al., 1998).
This downregulation of CCRs occurs at both transcriptional and post-transcriptional
levels and is accompanied by an increase in CCR7 expression (Hirao et al., 2000). This
increase in CCR7 and decrease in inflammatory CCRs allows the mature DCs to migrate
away from the inflamed site toward nearby draining lymph tissues. CCR7 binds CCL19
and CCL21, which are constitutively produced on endothelial and stromal cells in B/Tcell areas of the lymph (Rot et al., 2004). This upregulation of CCR7 on mature DCs
brings them into close contact with lymphocytes, specifically T cells, to present antigen
via MHC class I or II (Ebert et al., 2005). This is the typical process of DC activation,
LN migration and presentation of antigen to T cells, and DC vaccines must be capable of
this migration in order to effectively stimulate antitumor T cell responses.
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pre-DC
DC to activated DC. Dendritic
Figure 1.2. Chemokine receptor expression from pre
cell precursors in peripheral blood express CCR2. These cells, once stimulated with GMGM
CSF, IL-4, Flt-3L
3L or other stimulants, differentiate into immature DCs expressing
inflammatory chemokine receptors CCR1, CCR2, CCR5, CCR6, CXCR1 and CXCR2.
These chemokine receptors allow recruitment of immature DCs to sites of inflammation,
following the inflammatory chemokine gradient. Once arriving at inflamed tissues,
danger signals and inflammatory cytokines permit DC maturation. Maturing DCs
undergo autodesensitization of inflammatory chemokine receptors, with concomitant
expression of inflammatory chemokines. Shortly thereafter, mature DCs express CCR7
and CXCR4, which allow for their departure from inflamed tissues (since they no longer
express inflammatory
lammatory chemokine receptors), and recruitment to secondary lymph tissues.
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1.6. Toll-like Receptors (TLRs)
The immune system is divided into two modes of protection: innate immunity
and adaptive or acquired immunity. The innate branch was long thought to induce nonspecific immunity, while the adaptive branch generated specific immune reactions via Tand B-lymphocytes. The ‘nonspecific’ definition of the innate immune system is being
reconsidered as it is becoming increasingly more apparent that there is quite a deal of
specificity involved. This modification of our understanding of innate immunity has
been primarily driven by the expanding knowledge of pattern-recognition receptors
(PRRs) and their ligation with pathogen-associated molecular patterns (PAMPs), as well
as the continued discovery of novel PRRs and PAMPs. PRRs are a broad class of
receptors that bind stress signals including microbial and synthetic components. They
include TLRs, CD14, NOD-like receptors (NLRs), RIG-like receptors (RLRs),
complement receptors, and C-type lectins (Palm et al., 2009). The subgroup TLRs has
probably received the most attention. TLRs have been highly conserved throughout
evolution, attributing to their biological importance. They are a subfamily of the larger
superfamily including IL-1Rs. Both IL-1Rs and TLRs have cytoplasmic TIR (Toll/IL1R) domains containing three signaling motifs. However, their extracellular (EC) regions
differ: IL-1Rs have three immunoglobulin-like domains and EC TLR regions consist of
stacks of leucine-rich repeats (LRRs) that are arranged into a horseshoe structure
(Iwasaki et al., 2004; Akira et al. 2004). To date there are ten TLRs identified in humans
and thirteen in mice. TLRs 1-10 are similar between human and mouse; however, the
functionality of murine TLR8 is questioned (Gorden et al., 2006). TLR1, -2, -4, -5 and -6
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are membrane-bound and TLR3, -7, -8 and -9 are located on endosomes within the cell,
which is expected since they recognize nucleic acid structures (most often viral). Here
we will focus on murine TLRs.
1.6.1. Dendritic Cells and TLRs
Dendritic cells are important mediators of TLR signaling since they are poised at
the interface of innate and adaptive immunity. TLR expression on DCs greatly depends
on the DC subset. CD4+ DCs express all murine TLRs except TLR3; CD8+ DCs lack
TLR5 and TLR7; CD4-CD8- DCs express TLRs1-9 (Edwards et al., 2003; Iwasaki et al.,
2004); and BMDCs express all TLRs except TLR3 and TLR7 (Dearman et al., 2009).
Interestingly, plasmacytoid DCs lack TLR3 which is one of the TLRs most prominent in
IFN-β production. It makes sense that different DC subsets have different TLR profiles
since they will encounter particular pathogens depending on their anatomical location.
This is yet another way the immune system regulates tailored immune responses.
1.6.2. Tailored Immune Responses by TLRs
It is becoming increasingly evident that the complexity of the innate immune
system may reach far beyond that of the adaptive. Each of the TLRs, although similar,
induces slightly different combinations of cytokine, chemokine and other immune
mediator profiles. Yet another level of regulation involves refined signaling with
different combinations of TLR ligands. These responses may also vary depending on the
type of cell they induce. One such way of regulating TLR responses is the recruitment of
different adaptor proteins to the TLR cascade (Re et al., 2004). Even within one TLR
ligand, there can be subtle differences that call for quite different responses. For
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example, it was recently discovered that three different forms of polyriboinosinicpolyribocytidylic acids (poly I:C) elicit three different gene profiles in phenotypically
mature DCs (Avril et al., 2009). Simultaneous activation of different TLRs can enhance
or even inhibit TLR signaling pathways. It has been shown that TLR8 inhibits TLR7 and
-9 and TLR9 inhibits TLR7 in HEK293 cells (Wang et al., 2006); this, however, has not
been confirmed in vivo. In essence, different combinations of TLR expression on a
particular cell type, the number of different signaling pathways that can be induced by
each TLR, and the synergistic or antagonistic effects of multiple TLR ligand induction
may induce millions of different gene profile combinations. Indeed, the complexity of
innate immunity intensifies as our knowledge of the field expands.
1.7. Inflammation and Cancer
There has been long standing evidence for the involvement of inflammation and
cancer. Infectious diseases causing chronic inflammation account for approximately onefourth of all cancers in developed countries (Balkwill et al., 2001). Helicobacter pylori,
Hepatitis B virus, Hepatitis C virus, and Epstein-Barr virus infections are all major
contributing risk factors for gastric cancer, hepatocellular carcinoma, and
lymphoproliferative disorders, correspondingly (Coussens, 2002). It was suggested that
these microbes encouraged oncogene activation, but it has since been recognized that
chronic inflammation is a major player in increased risk factors for certain cancers
(Coussens, 2002). Most common cancers associated with chronic inflammation include
the aforementioned as well as cervical (Castle et al., 2001), lung (Lee et al., 2009),
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bladder (Michaud, 2007), esophageal (Deans et al., 2006), pancreatic (Farrow et al.,
2002) and prostate cancers (Palapattu et al., 2005).
Along with the correlation between chronic inflammation and cancer, there is also
an association of decreased risk for certain cancers with the prolonged used of NSAIDs
(non-steroidal anti-inflammatory drugs), which is linked to the inhibitory effect on NFκB
transcription factors (Garber, 2003). Aspirin, the archetype of NSAIDs, has been
demonstrated to play a protective role against colorecal cancer (Dube et al., 2007),
esophageal and gastric cancers (Gonzalez-Perez et al., 2003), and breast cancer (Zhao et
al., 2009). Karin and Greten pointed out that not only does long-term use of NSAIDs
correlate with decreased risk for certain cancers, but the use of ginseng, green tea,
resveratrol and curcumin also benefit the reduction of cancer occurrence (Karin et al.,
2005). These compounds all share inhibitory activities on the NFκB family of
transcription factors that are responsible for inducing many of the inflammatory
cytokines and chemokines (Bharti et al., 2002). So it seems as though inhibiting
inflammation via downregulation of NFκB may be the key to decreasing risk factors for
inflammation-associated cancers.
NFκB represents a family of five transcription factors including NFκB1
(p105/p50), NFκB2 (p100/p52), RelA (p65), RelB and c-Rel. The latter three are all
capable of binding DNA, however, p105 and p100 must be cleaved from NFκB1 and
NFκB2, respectively, to release the corresponding DNA binding subunits p50 and p52
(Caamano et al., 2002). Different combinations of NFκB subunits dimerize to achieve
tailored responses to specific stimuli. All five members, p50, p52, RelA, RelB and c-Rel,
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contain Rel homology domains (RHD) that are responsible for dimerization and DNA
binding; and the RHD is also where inhibitory IκB family members interact with NFκB
subunits (Ghosh et al., 1998). NFκB dimers are held inactive in the cytoplasm by IκB
proteins. The primary inhibitory proteins include IκBα, IκBβ, IκBε, p100 and p105. In
order for the NFκB dimers to travel to the nucleus, they must be released from the IκBs.
Upon appropriate stimulation, IκB kinases (IKKs) are activated which in turn
phosphorylate IκBs. There are three main subunits of the IKK complex, IKKα, IKKβ
and IKKγ (NEMO). Typically, IKKβ is involved with inflammatory cascades, whereas
IKKα is primarily implicated in morphogenic signaling. NEMO is the regulatory subunit
of this complex in that its activation is required for IKKα and IKKβ phosphorylation of
IκBs (Rothwarf et al., 1998). IKKs phosphorylate IκBs making them targets for
ubiquitination and subsequent degradation, releasing the NFκB subunits and allowing
their nuclear translocation.
Tollip, an adaptor protein first discovered in the IL-1R pathway (Burns et al.,
2000), has since been identified as an inhibitory protein for certain TLR pathways (Zhang
et al., 2002). Induction of IL-1R and most TLRs stimulates pro-inflammatory mediators,
hence Tollip is involved in minimizing or suppressing the induction of inflammation. It
does not act via direct NFκB inhibition, but rather acts upstream to inhibit IRAK1 (Zhang
et al., 2002). Upon stimulation of TLR ligands, particularly TLR2 and TLR4, IRAK4 is
brought into close proximity with IRAK1 and phosphorylates IRAK1 causing the release
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of Tollip and downstream activation of the TLR pathway. It acts in a similar manner in
IL-1R signaling, to suppress IL-1 induced signaling (Burns et al., 2000).
NFκB inhibitors are constantly being researched in efforts to develop drugs to
treat such diseases as asthma, autoimmune, arthritis and certain inflammation-associated
cancers. Many plant-based compounds have been identified to interfere with the
inflammatory pathway by specifically inhibiting NFκB activation. These include many
antioxidants such as curcumin, quercetin, epigallocatechin 3-gallate (EGCG), fungal
products and many other compounds (Nam, 2006). Curcumin has been shown to inhibit
NFκB in a dose-dependent manner, and its mechanism of action may by hinged to the
induced expression of HSP70 (Dunsmore et al., 2001). Besides its inhibition of NFκB
signaling, quercitin has also been shown to reduce constitutive NFκB activation in human
prostate cancer cells (Nam, 2006). EGCG, the most reputable biologically active
component of green tea, inhibits NFκB by inhibiting degradation of IκB via inhibition of
IKK activity in both cancer cells and normal cells (Yang et al., 2001). Three fungal
products, cycloepocydon, gliotoxin and panepoxydone, are known NFκB inhibitors.
Umezawa and colleagues tested these three NFκB inhibitors for their potential to reverse
the constitutive NFκB-induced protection from apoptosis in tumor cells, and their results
were promising for cancer therapies (Umezawa et al., 2000). These compounds show
potential for the future development of anti-inflammatory drugs as well as
chemopreventive agents.
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1.8. Morinda citrifolia (Noni)
Morinda citrifolia (Noni) has been used for centuries to treat an array of maladies.
It is a small evergreen tree native to South Asia, with elongated leaves, white tubular
flower clusters, and greenish fruits that ripen to whitish-yellow. Its popularity has been
on the rise particularly since the relaxed FDA guidelines for dietary supplements (Wang
et al., 2002) and the advent of Tahitian Noni International. Because of this, scientific
research on Noni has expanded greatly over the last decade. The main objectives are to
ensure its safety as a food product and to identify components responsible for its
purported effects. Although its oldest uses primarily involved topical application of
leaves and roots, the fruit has been more popular for modern usage (Pawlus et al., 2007).
Fermented Noni is the most traditional method of consumption. Its fruits are harvested,
collected into glass jars and allowed to ferment for several hours up to several weeks
(Dixon et al., 1999). The documented, scientifically researched effects of Noni include
anti-inflammatory, antiangiogenic, anticancer, antibacterial and antioxidant. Here we
will focus on the applications and components of Noni fruits and their aforementioned
effects.
Noni has been reported to modulate immune cells and has been implicated in
enhancing the adaptive immune response by activating T and B cells. There is growing
concern about the administration of antibiotics to production animals, therefore, new
methods for boosting immune systems of livestock has been hotly pursued. Since Noni
has long standing reports of being an immunomodulator, it is not surprising that it is
being considered for the treatment of neonatal and newborn calves. In one such study,
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Noni was used as a bactericidal supplement for calves and delivered promising results
with enhanced killing of Escherichia coli (Schafer et al., 2008). There is also a patent on
Noni formulations for immunomodulation of T cells in neonatal stock animals, an
important mediator for resisting bovine RSV, a common cause for death of newborn
calves (Darien et al., 2007). A study in 2008 revealed the immunomodulation of B cells
as a result of direct DC stimulation with fermented Noni exudate. Murine DCs were
treated with Noni for 24 hours, washed, then cocultured with splenocytes. Interestingly,
the population of proliferative splenocytes was primarily B cells; and not only were B
cells stimulated to divide, but they also underwent differentiation and Ig class switching
(Zhang et al., 2009). Thus, Noni has obvious effects on the adaptive branch of immunity
and may play an important role in future livestock management.
Traditional uses for Noni have included treatment for sprains, menstrual
difficulties, arthritis, asthma and general swelling (Wang et al. 2002), all of which are
associated with inflammation. One possible mechanism of the anti-inflammatory effects
of Noni has been explained by Palu and colleagues. Here it was reported that Noni
activates cannabinoid receptors, specifically CB2, in a dose-dependent manner (Palu et
al., 2008). CB2 activation is associated with anti-inflammation. Also, Morinda
morindoides, a close cousin of Noni, was shown to inhibit complement factors, which
substantiates its use for treating rheumatic pains (Cimanga et al., 2003). These two
mechanisms are only part of Noni’s arsenal for inducing anti-inflammatory effects; the
others may be attributed also to its antioxidant properties.
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Antioxidant activity of Noni has been credited to several compounds, namely
coumarin derivatives, scopoletin, 7-hydroxycoumarin (7-HC) and 4-HC, a novel
anthraquinone, two novel iridoid glucosides, and quercetin (Ikeda et al., 2009).
Scopoletin is a well kown antioxidant and has been attributed to antimicrobial and antiinflammatory activities (Deng et al., 2007). The novel anthraquinone (2-methoxy-1,3,6trihydroxyanthraquinone) was found to be nontoxic at high doses and nearly 40 times
more potent at reducing quinone than the positive control (Pawlus et al., 2005). A
detailed study by Deng and colleagues revealed eight compounds of Noni that inhibited
lipoxygenase. These included scopoletin and two novel lignans, a lactone and (+)-3,3’bisdemethyltanegool (Deng et al., 2007). In 2005, a novel lignan, Americanin A, was
identified in Noni and it was confirmed to be a potent antioxidant (Su et al., 2005).
Based on the recent detailing of the chemical constituents of Noni and their antioxidant
activities, science is able to start backing the claims held by Noni users for centuries.
Lastly, Noni has received much attention for its antiangiogenic and anticancer
properties in both animal models and clinical settings; however, the mechanisms
underlying this effect are largely unknown. The first attempt to identify the component
of Noni responsible for its antitumor activities described a water-soluble, ethanolprecipitable, polysaccharide-rich substance from Noni fruit as the immunomodulator
(Hirazumi et al., 1999). Importantly, this report was the first to note the enhanced
chemotherapeutic activities of Noni. Shortly thereafter, Wang and Su identified Noni to
inhibit DMBA-DNA adduct formation (Wang et al., 2001), implicating its protective role
in chemically induced cancers. In 2003, Furusawa and Hirazumi expanded their research
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to demonstrate the antitumor properties of Noni precipitate (ppt) were dependent on
macrophages, NK cells and T cells and extended its synergistic effects with even more
chemotherapies (Furusawa et al., 2003). Also in 2003, Noni was tested for
antiangiogenic effects and was found to inhibit new vessel sprouts at 5% concentration
and induce vessel degeneration at 10% concentration (Hornick et al., 2003). The most
recent account of antitumor activity by Noni confirmed the necessity of NK cells and T
cells for tumor eradication (Li et al., 2008). Noni was shown to be effective at both
cancer prevention and treatment within S180 and Lewis Lung tumor models. It is worth
noting, mice that cleared tumor burden were rechallenged after two months, and all
rejected the tumors; five months later the same mice were challenged again and 15 of 16
mice rejected the tumors. The strong animal evidence for anticancer properties of Noni
has encouraged its research, and with time we are beginning to understand its
mechanisms of action.
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2.1. Abstract
Dendritic cell-mediated cancer immunotherapy employs several ways to engage
tumor antigens. We have demonstrated in both pre-clinical animal studies and early
clinical trials that dendritomas, highly purified hybrids between dendritic cells (DC) and
tumor cells, are superior activators of anti-tumor immunity. It has been argued, however,
that DC vaccines may be dysfunctional in lymph node migration. In the present study we
examined inflammatory chemokine and chemokine receptor expression as well as other
maturation induced genes in dendritomas produced from either immature or mature DCs
in order to shed light on their capacity to migrate from injection sites to draining lymph
nodes and elicit an appropriate immune response. RNA microarray analysis was used to
identify gene expression profiles for inflammatory chemokines and receptors and other
maturation induced genes within dendritomas, lysate-pulsed dendritic cells, immature
DCs and mature DCs. Gene regulation was confirmed with relative quantification, realtime RT-PCR in a separate experiment. We found that fusion of immature DCs to tumor
cells initiates maturation with respect to inflammatory chemokines, chemokine receptors
and other maturation induced genes in a similar pattern as LPS matured DCs.
Interestingly, we saw a reversed gene profile when mature DCs were fused to tumor cells.
LPS matured DCs displayed the chemokine repertoire expected with DC maturation;
however, once fused to tumor cells, these chemokines and other maturation induced
genes reverted to levels comparable to immature DCs. It appears that mature DCs used
for dendritoma production result in a de-mature phenotype. Our results indicate that
dendritomas from immature DC/tumor cell fusions may be more effective in migration
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from injection site to draining lymph nodes and, therefore, would be more effective in
stimulating anti-tumor immunity.
2.2. Introduction
Dendritic cells (DC) are professional antigen presenting cells, which play a vital
role in stimulating immune responses against infections and tumor cells (Banchereau et
al., 1998; Hart, 1997; Dunn et al., 2002). DC-mediated cancer immunotherapy is aimed
at picking up where the host immune system failed by presenting tumor antigens to innate
and adaptive effector cells, thus stimulating anti-tumor immunity for immediate therapy
and latent protection (Ullrich et al., 2008; Banchereau et al., 2002; Steinman et al.,
2006). Three basic approaches have been employed to engage DCs with tumor antigens:
tumor antigen pulsing, genetic modification with tumor antigen genes or RNA, and
DC/tumor fusion (Schuler et al., 2003; Svane et al., 2003). Although all three
approaches have been widely utilized and have successfully increased tumor-antigen
reactive T cells in periphery, the DC/tumor hybridoma vaccine has proved more effective
since this strategy provides a broader diversity of known and unknown tumor antigens as
well as MHC class I and MHC class II antigens to the immune system (Ward et al., 2002;
Shimizu et al., 2004).
Most DC hybridoma studies have utilized fusion mixtures as a vaccine due to the
lack of selective markers on fused DC/tumor cells to purify hybrids from the fusion
mixture (Haigh et al., 1999). The immune response stimulated by this mixture is
compromised due to the presence of large numbers of unfused cells or self/self fused
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cells. In order to solve this problem, we developed a novel hybrid purification
technology that instantly purifies DC/tumor hybrids from the mixture (Holmes et al.,
2001). Animal studies demonstrated that highly purified DC/tumor hybrids, or
dendritomas (DT), are superior activators to stimulate anti-tumor immunity compared
with fusion mixtures (Li et al., 2001). Several clinical trials using dendritoma vaccines
have been conducted; and data shows that DT vaccines stimulate anti-tumor immune
responses in some patients and demonstrate observable clinical responses (Wei et al.,
2006; Wei et al., 2007).
On the other hand, although most DC hybridoma vaccines were effective in
preclinical animal studies, clinical trials have shown less encouraging results (Gong et
al., 2008). Consequently, an important field in DC mediated cancer immunotherapy is to
understand and solve the inconsistencies between animal studies and human clinical
trials. The increase of regulatory T cells and tolerogenic DCs found in tumors after DC
vaccine administration are two of the major factors suppressing anti-tumor immunity
(Steinman et al., 2003; Li et al., 2007; Dannull et al., 2005). Others include DC
procurement, route of administration, and tumor microenvironment (Melief et al., 2008;
Grover et al., 2006). The overall belief is that DCs must be presented with maturation
stimuli and tumor antigen, administered through an appropriate route for different cancers
with mediators aiding their lymph node migration, and have the capacity to process and
present both MHC I and II peptides in order to acquire therapeutic and long-term
protective immunity (Ueno et al., 2006). Much research has been done to progress DC
vaccination in most of these areas; however, information on the migratory capacity of DC
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vaccines is still needs attention. It is imperative to understand the factors involved in the
migration of dendritomas, and other DC vaccines, to the draining lymph nodes where
they encounter and activate effector T cells.
Inflammatory chemokines, such as macrophage inflammatory protein 1alpha
(MIP-1α) and RANTES (CCL3 and CCL5, respectively), are predominantly located at
nonlymphatic sites of inflammation where they recruit immune cells to participate in
antigen presentation and recognition to ultimately elicit a cell-mediated response to
infection or tumor cells. Immature DCs (iDC) typically express inflammatory chemokine
receptors CCR1, CCR2 and CCR5 which bring them into contact with antigens at
inflammatory sites (Sozzani et al., 2000). Once antigen uptake has ensued, DCs rapidly
increase production of inflammatory chemokines and lose responsiveness to these CCLs,
a process called autodesensitization (Sallusto et al., 2000), allowing for reverse
transmigration of activated, mature DCs (mDC) into secondary lymphoid tissues where
they present antigen to effector cells. Clearly, the completion of this process is essential
for effective DC vaccines. In the present study, in order to understand whether
dendritomas are capable of effective migration to secondary lymphoid tissues, we
examined the regulation of key chemokines and chemokine receptors along with several
maturation induced genes. Our microarray and real-time RT-PCR results demonstrate
that fusing tumor cells to iDCs matures them with respect to ccr and ccl expression, while
fusing tumor cells to mDCs causes the reversal of ccr and ccl expression by mDCs. Our
results implicate immature DCs as better choice for dendritoma production, and a
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migratory mediator adjuvant may be needed when mature DCs are used for dendritoma
production.
2.3. Materials and Methods
2.3.1. Mice and Tumor Cells
Female C57BL/6J mice at 6-8 weeks of age were purchased from Jackson
Laboratories (Bar Harbor, ME) and housed in our pathogen-free animal facilities.
Animal experiments were carried out in accordance with both Guidelines for the Care
and Use of Laboratory Animals (NIH Publication number 85-23) and institutional
guidelines. Murine acute myeloid leukemia cell line C1498 and murine melanoma cell
line B16F0, both C57BL/6J-derived, were maintained in complete DMEM (Gibco BRL,
Grand Island, NY) supplemented with 10% FBS (Hyclone, Logan, UT) and 50 µg/ml
gentamicin (Gibco BRL) at 37 °C in a humidified atmosphere of 5% CO2.
2.3.2. Dendritic Cells
Bone marrow derived DCs were cultured as previously described (Lutz et al.,
1999). Briefly, bone marrow cells flushed from C57BL/6J mouse femurs and tibiae with
RPMI-1640 (Gibco BRL) were filtered through 40-µm nylon cell strainers. After the
removal of RBCs by ACK lysate (Lonza, Allendale, NJ), the remaining cells were
resuspended in DC medium containing RPMI-1640 supplemented with 10% FBS, 50
µg/ml gentamicin, and 20 ng/ml rmGM-CSF (Sigma, St. Louis, MO) and plated at 45x106 cells/10 ml in a 100-mm tissue culture dish. On day 4, 10 ml fresh DC media was
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added to each dish. On day 8, non-adherent and loosely adherent cells were harvested,
washed with RPMI-1640 and replated in fresh DC medium containing 10 ng/ml rmGMCSF with or without 100 ng/ml LPS (Sigma). On day 10, non-adherent and loosely
adherent cells were collected for further studies.
2.3.3. Pulsing DCs with Tumor Lysate
B16F0 cells were collected and resuspended in a conical tube in 1x PBS at a
concentration of 1x107cells/mL. The tube with cell suspension was immersed in a dryice/methanol bath for approximately 3 minutes. Once frozen, the cells were placed in a
37°C water bath with gentle agitation and thawed completely. The process was repeated
for a total of four freeze/thaw cycles. The cells were then centrifuged at 15,000 x g for
10 minutes at 20°C and supernatant was collected. Protein concentration was determined
using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). Either immature DCs (iDC)
or LPS matured DCs (mDC) were incubated with 100µg/mL tumor protein lysate
overnight. Pulsed DCs (LPiDC or LPmDC) were then centrifuged at 300 x g to collect
cells but discard lysate in the supernatant. Cells were washed three times in 1x PBS prior
to RNA extraction.
2.3.4. Cell Staining and Fusion
DCs and tumor cells were stained green and red, respectively, using PKH67-GL
or PKH26-GL kits (Sigma) according to manufacturer’s protocol. Stained cells were
washed thrice to remove unbound dye and tumor cells were irradiated with 50 Gy. Tumor
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cells and DCs were fused at a ratio of 1:1 or 1:2 using a 50% PEG 10% DMSO solution
(Sigma). After fusion, cells were incubated overnight in DC medium.
2.3.5. FACS Sorting
The fusion mixtures were harvested (both adherent and non-adherent) and
resuspended in PBS at a concentration of 1x107 cells/ml. Cells were sorted on a BD
FACSCalibur (Becton Dickinson, San Jose, CA) according to the dual fluorescent colors.
Sorted cells, labelled as dendritomas (DT), were resuspended in DC medium and
incubated overnight with or without 100 ng/ml LPS prior to RNA extraction.
Dendritomas exhibited both green and red fluorescence and purity was greater than 95
percent.
2.3.6. Microarray
LPiDC, LPmDC, DT, DC, and tumor cell RNA was extracted using
ArrayGradeTM Total RNA Isolation Kit (SABiosciences, Frederick, MD) and was sent
for pathway-focused GEArray service using mouse Dendritic and Antigen Presenting
Cell Oligo GEArray (SABiosciences). Analysis was performed using the GEArray
Expression Analysis Suite software (SABiosciences).
2.3.7. Real-time PCR
Real-time one-step RT-PCR was performed on total RNA via an Eppendorf Mastercycler
ep Realplex2 (Eppendorf, Westbury, NY) using QuantiTect Primers optimized for
QuantiTect SYBR Green RT-PCR kit (Qiagen, Valencia, CA). Results were normalized
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to β-actin, which was chosen over gapdh and β2M as the housekeeping gene, since it was
least affected by treatment. Data was analyzed by ∆∆Ct calculations.
2.4. Results
2.4.1. Tumor lysate matures iDCs
Overnight incubation of iDC with B16F0 tumor cell lysate induced DC
maturation with respect to inflammatory chemokine and chemokine receptors. iDCs
express high levels of inflammatory receptors: CCR2 and CCR5 and low levels of
inflammatory chemokines: CCL3, CCL5 and CCL22. Upon antigen uptake and
processing, iDCs are induced to decrease levels of inflammatory receptors, while
increasing inflammatory chemokine expression. Microarray analysis shows tumor lysate
pulsed iDCs (LPiDCs) displayed a drastic reduction in ccr2 and ccr5 and an increase in
inflammatory and inducible chemokines ccl3, ccl5 and ccl22; their levels were nearly
identical to DCs matured with LPS (Figure 2.1A).
DCs cultured from C57BL/6J mice were matured with LPS on day 8 of culture.
On day 10, they were incubated with B16F0 tumor lysate and RNA was extracted after
overnight incubation. RNA microarray shows that tumor lysate pulsing of mDCs
(LPmDC) caused no change in expression of ccr2, ccr5, ccl3, ccl5, or ccl22 compared to
LPS matured DCs (mDC, Figure 2.1B).
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Figure 2.1: Tumor lysate pulsing matures iDC, but causes no change in mDC
Total RNA was extracted from iDC, LPiDC, mDC, and LPmDC and was analyzed by
RNA microarray for the indicated chemokine and chemokine receptors. (A) Gene
expression profiles of LPiDC and mDC compared to iDC. (B) Gene expression profiles
of LPmDCs compared to mDC.
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2.4.2. Fusion with tumor cells matures iDC
iDCs were fused with B16F0 tumor cells by PEG in a 2:1 ratio. The fused
hybrids (immature dendritomas or iDT) were purified from the fusion mixture by dual
fluorescent FACS sorting on day 11. RNA was extracted from iDTs following collection
and used for RNA microarray. As shown in Figure 2.2A, iDTs dramatically decreased
expression of ccr2 and ccr5, but increased ccl3, ccl5 and ccl22 as compared to iDCs.
This pattern is consistent with the expression of mDCs and LPiDCs (Figure 2.1A);
therefore, fusion of iDC with tumor cells instigates maturation with respect to these
inflammatory chemokines and receptors. To further confirm this finding, real-time RTPCR was performed to measure the change of expression in ccr2, ccr5, ccl3, ccl5, and
ccl22 in iDTs. The results, as shown in Figure 2.2B, demonstrate a similar pattern of
expression: down-regulation of ccr genes and up-regulation of ccl genes.
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Figure 2.2: Fusion with tumor cells matures dendritic cells. iDCs were fused with
C1498 or B16F0 tumor cells in a 1:1 or 2:1 ratio using PEG in two separate experiments.
The fusion hybrids (iDT) were generated by FACS sorting based on the DT technology
(see Materials and Methods). Total RNA was analyzed by RNA microarray and realtime RT-PCR for the indicated genes. (A) Microarray analysis of chemokine and
chemokine receptor gene expression by iDTs, iDC = 1. (B) Real-time RT-PCR analysis
of chemokine and chemokine receptor gene expression by iDTs, iDC = 1. (*p<0.05,
**p<0.01 ***p<0.001)
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Additional genes associated with LPS induced DC maturation were examined in
two independent microarray experiments in iDTs made from either C1498 tumor cells or
B16F0 tumor cells. As shown in Figure 2.3, acpp, atf4, clec4d, ifit1, il-1b, g1p2, and
prg1 were upregulated (Figure 2.3A), while cd209a, f13a1, icosl, ifi30, ifngr1, rnase6,
and s100a4 were downregulated (Figure 2.3B), indicating that fusion of iDCs and tumor
cells yields a maturing hybridoma.
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Figure 2.3: Fusion of iDCs with tumor cells yields a similar gene profile to LPS
matured DCs. iDCs were fused with C1498 or B16F0 tumor cells in a 1:1 or 2:1 ratio
using PEG in two separate experiments. The fusion hybrids (iDT) were generated by
FACS sorting based on the DT technology (see Materials and Methods). Total RNA was
analyzed by RNA microarray for the indicated genes. (A) Genes upregulated by both
iDTs and LPS matured DCs compared to iDCs. (B) Genes downregulated by iDTs and
LPS matured DCs compared to iDCs.
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2.4.3. Fusion with tumor cells reverses the maturation for mDTs
DCs cultured for 8 days were matured with LPS for two days and fused with
B16F0 tumor cells. The hybrids (mature dendritomas or mDT) were purified from the
fusion mixture using the same technology described above. RNA microarray established
the increased expression of ccr2 and ccr5, while the expression of ccl3, ccl5, and ccl22
decreased (Figure 2.4A): a clear pattern of DC de-maturation with respect to
inflammatory ccl and ccr. This finding is in contrast to lysate pulsed mDCs where no
significant change was observed (Figure 2.1B). Real-time RT-PCR also confirmed the
change of expression in ccr2, ccr5, ccl3, ccl5, and ccl22 in mDTs. The results, shown in
Figure 2.4B, are consistent with microarray data: ccr genes are upregulated and ccl genes
downregulated. Additional genes of interest analyzed by microarray of mDTs showed a
similar pattern compared to iDCs. Cd209a, f13a1, marcks, rpl13a, cd207, cdc42, and
pfn1 were upregulated (Figure 2.5A), while acpp, atf4, clec4d, il-1b, il-12b, cd36, sod2,
cd80, pnrc1 and tnfsf4 were downregulated (Figures 2.5B), further supporting dematuration of mDTs.
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Figure 2.4: Fusion of mDCs with tumor cells (mDT) yields an opposing
chemokine/chemokine receptor pattern to mature DCs. mDCs were fused with
B16F0 tumor cells in a 2:1 ratio using PEG. The fusion hybrids, mDT, were generated
by FACS sorting based on the DT technology (see Materials and Methods). Total RNA
was analyzed by RNA microarray and real-time RT-PCR for the indicated genes. (A)
Microarray analysis of chemokine and chemokine receptor gene expression by mDTs,
mDC = 1. (B) Real-time RT-PCR analysis of chemokine and chemokine receptor gene
expression by mDTs, mDC = 1. (*p<0.05, **p<0.01 ***p<0.001)
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Figure 2.5: Fusion of mDCs with tumor cells de-matures mDTs. mDCs were fused
with B16F0 tumor cells in a 2:1 ratio using PEG. The fusion hybrids, mDT, were
generated by FACS sorting based on the DT technology (see Materials and Methods).
Total RNA was analyzed by RNA microarray for the indicated genes. (A) Genes
upregulated by both mDTs and iDCs compared to mDCs. (B) Genes downregulated by
mDTs and iDCs compared to mDCs.
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2.5. Discussion
Tumor lysate pulsed immature DCs (LPiDCs) are mature compared to iDCs.
LPiDCs express increased levels of CD80, CD86, and CD40 costimulatory molecules as
well as molecules involved in antigen presentation while decreasing those involved with
antigen uptake (Paglia et al., 1996; Berard et al., 2000). For the first time, we show that
LPiDCs are activated to elevate ccl levels and decrease ccr levels (Figure 2.1A),
suggesting that antigen-pulsing results in efficient DC activation to mediate the
chemokine receptor paradigm switch in the absence of other inflammatory stimuli or
microbial products such as LPS.
We did not observe any significant change in the genes analyzed by microarray
for tumor lysate pulsed, LPS matured DCs (LPmDCs, Figure 2.1B). This could be due to
the notion that LPS matured DCs have downregulated antigen-uptake mechanisms, or
compared to microbial danger signals, tumor lysates are weak DC maturation agents.
Interestingly, it has been shown that coincubating mDCs with CCR7 ligands,
CCL19/ELC or CCL21/SLC, re-stimulates endocytosis by previously matured DCs
(Yanagawa et al., 2003); therefore, it seems plausible to induce mDC uptake of tumor
lysate by concomitant incubation with a CCR7 ligand. Based on our data, it would be
better to use iDCs to engage tumor antigens; nonetheless, it would be interesting to
observe the effects of pulsing mDCs with tumor lysate combined with ELC or SLC.
iDTs, composed of tumor cells and iDCs, express increased levels of ccl genes
and decreased ccr genes (Figure 2.2). This process is assumed to be mostly due to the
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autocrine action of chemokines on their respective receptors expressed by DCs (Kikuchi
et al., 2001; Sozzani et al., 1998); although it has been shown that C5a and fMPL do not
have this autodesensitization effect on DCs (Sozzani et al., 2000). In addition to the ccl
and ccr paradigm switch, iDT maturation is also accompanied with up-regulation of
genes such as acpp, atf4, clec4d, ifit1, il-1b, g1p2, and prg1 and down-regulation of
cd209a, f13a1, icosl, ifi30, ifngr1, rnase6, and s100a4 as confirmed in two separate
microarray analyses and also observed in canonical DC maturation when iDCs are
matured with LPS (Figure 2.3). Again, our data points to successful maturation when
iDCs are fused to tumor cells (iDTs) which is important when designing DC vaccines.
Interestingly, we observed that iDTs expressed high levels of il-10 in two separate
microarrays, while mDTs expressed non-detectable levels of il-10 (data not shown),
contradicting other reports where both iDC/tumor fusions and mDC/tumor fusions have
elevated levels of IL-10 (Vasir et al., 2008). This may implicate the need for
simultaneous addition of a danger signal to overcome IL-10 production when
manufacturing iDTs. More studies are needed to clarify the role of IL-10 in this process.
Mature DCs used for fusion oddly de-mature, whereas iDCs are matured with
fusion to tumor cells. Interestingly, the ccl and ccr expression of mDTs was completely
reversed compared to iDTs and mDCs. There was a significant decrease in ccl
expression with a compensating increase in ccr expression (Figure 2.4), closely
mimicking the ccr and ccl expression of iDCs. This phenomenon may be due to
complete washing of mDCs before fusion, which frees the supernatant of CCLs, no
longer triggering autodesensitization. Taking this into account, mDTs may not be as
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good as iDTs for migration from injection sites to draining lymph nodes. Not only did
mDTs de-mature with respect to ccr and ccl expression, but they also upregulated
cd209a, f13a1, marcks, rpl13a, cd207, cdc42, and pfn1, and downregulated acpp, atf4,
clec4d, il-1b, il-12b, cd36, sod2, cd80, pnrc1 and tnfsf4 (Figure 2.5) in synchrony with
iDCs. Our data suggest mDTs may need restimulation with CCLs or possibly other
danger signals in order to resume proper migratory capacity and antigen presentation
since they seem to have more genes in common with iDCs than mDCs. It is possible that
stimulating dendritomas with microbial danger signals or adjuvants could overcome this
problem as seen with pre-treatment and post-treatment with OK432 and CpG ODN
increasing the effectiveness of DC fusion vaccines (Li et al., 2008; Koido et al., 2007a;
Koido et al., 2007b).
In conclusion, our data unfolds a significant pattern of chemokine expression in
dendritomas depending on the maturation state of DCs and demonstrates the plasticity of
LPS matured DCs used for vaccine preparation. Although mature DCs are preferred to
reduce tolerance or expansion of regulatory cells, we see here there may be problems
with migration and induction of immune response. To circumvent this problem, either
immature DCs should be used for fusion with simultaneous addition of a danger signal
such as LPS, OK432, or CpG ODN to properly mature the DCs and abrogate production
of IL-10; or if mature DCs are used for fusion, it must be investigated to see if they can
be re-stimulated to secrete CCLs, down-regulate CCRs, and reclaim maturation in order
to properly migrate and activate an immune response against presented tumor antigens.
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3. MORINDA CITRIFOLIA (NONI) AS AN IMMUNOMODULATOR
OF DENDRITIC CELLS: INHIBITION OF TOLL-LIKE
RECEPTOR AND NFκB PATHWAYS AND PROCUREMENT OF
ANTI-INFMMATORY MEDIATORS
3.1. Abstract
Morinda citrifolia (Noni) has been used for centuries to treat a wide range of
maladies. Its current growth as a dietary supplement to enhance the immune system has
demanded more scientific research into its purported effects. Whereas most previous
reports have been self-published, recent information has been described in peer-reviewed
scientific journals on the anticancer, anti-inflammatory, and immunomodulatory effects
of Noni. Also, fermented Noni exudate was shown to activate dendritic cells, one of the
key players in innate and adaptive immunity. Noni fruit contains a wide variety of
microorganisms, and upon fermentation all but one are killed, resulting in a large array of
pathogen-associated molecular patterns (PAMPs), potentially activating patternrecognition receptors. Since dendritic cells express a wide variety of Toll-like receptors
(TLRs), we hypothesized that Noni-treated dendritic cells would alter the expression of
inflammatory genes downstream of TLR pathways. The expression of tnf, il-6, ptgs2,
ccl3 and ccl5 were examined in Noni-stimulated bone marrow-derived dendritic cells.
Furthermore, in a second experiment, dendritic cells were treated with endotoxindepleted Noni and 84 genes in the TLR pathway were evaluated. Both experiments were
carried out by real-time RT-PCR with SYBR green chemistry. FACS analysis also
revealed an intriguing shift from a CD11c+CD83+ dendritic cell population to a much
larger Mac-3+ population. Overall, Noni induced low levels of inflammatory cytokines,
significantly increased anti-inflammatory mediators, and inhibited elements of TLR

47

signaling, specifically NFκB. Gradually, Noni’s molecular mechanisms of action on
immune cells are being unraveled, and will hopefully clarify its antitumor and antiinflammatory roles for possible drug development.
3.2. Introduction
Morinda citrifolia, commonly known as Noni in the US and Hawaii, is
widespread throughout Polynesia, Southeast Asia, India, and Australia. It was brought to
the Pacific Islands more than 2000 years ago as the ancient Polynesians second most
popular medicinal herb. Cultures throughout the region have, for millennia, employed
every part of the plant as a food staple and for an immense range of illnesses and
ailments, including bacterial and viral infection, fungus, cancer, AIDS, high blood
pressure, and much more. In all, there are 40 known and recorded uses for the plant in
herbal remedies. In addition, the leaves of the plant have been used to produce dyes for
clothing and other textiles (Wang, 2004; Pawlus et al., 2007).
Noni grows as a small evergreen tree. It reaches 12-15 feet in height, is decorated
with large bright green elliptical leaves, columnar white flowers and lumpy yellow fruit,
about the size of a potato. Its seeds have an air sac at one end, giving them the buoyancy
they need to float across the pacific and take root in islands throughout the region, to earn
the name “ocean-going Noni,” as the plant has been called in some regions. Finally, the
Noni fruit can be identified by its rancid odor and foul taste – justifying another popular
name – the “cheese fruit” (Dixon et al., 1999; Wang et al., 2002)
Extensive research is ongoing to identify both known and novel active
compounds of Noni. These include, but are not limited to, novel anthraquinones,
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saccharide fatty acid esters, glycosides, iridoid glucosides and damnacanthal (Akihisa et
al., 2007; Guangming et al., 2001; Su et al., 2005; Hiwasu et al., 1999; and Kamata et
al., 2006). Currently, several potent antioxidants and anti-inflammatory agents have been
extracted and identified (Pawlus et al., 2007; Deng et al., 2007; Pawlus et al., 2005;
Ikeda et al., 2009; Su et al., 2005). Besides isolated compounds, different fractions of
Noni have been studied for immunomodulatory effects. A polysaccharide-rich
precipitate of Noni juice has been found to have antitumor potential (Hirazumi et al.,
1999; Furusawa et al., 2003). Raw Noni, or Noni puree, shows antiangiogenic, cancer
preventive and bactericidal properties (Wang et al., 2001; Wang et al., 2002; Wang et al.,
2008; Hornick et al., 2003; Palu et al., 2007; Schafer et al., 2008). Wong reported two
case studies involving patients with adenocarcinoma self medicating with fermented
Noni. The first patient began drinking Noni on his deathbed after refusing medical
treatment, and showed no evidence of disease a year after diagnosis. The second patient,
who underwent surgery and had metastases in 17 of 28 lymph nodes tested, survived
sixteen years disease-free with the Noni treatment (Wong et al., 2004). This is extremely
significant since less than ten percent of patients survive even five years with this level of
metastasis.
Recently, our lab has examined the immunomodulatory effects of fermented Noni
exudate (fNE) in animal models. It was found that dendritic cells (DCs) cultured with
fNE are capable of inducing B cell proliferation, differentiation and even Ig class
switching (Zhang et al., 2009). Furthermore, fNE was found to be effective for both
prevention and treatment of mice with S180 sarcomas and Lewis Lung carcinomas (Li et
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al., 2008; Furusawa et al., 2003). These studies clearly demonstrated that both the innate
and adaptive immune systems are involved in the antitumor effect induced by fNE.
Although fresh Noni fruit has a myriad of microflora, upon fermentation, only one
fungus remains in fNE (personal communication, Marisa Wall, 2009). Our lab also
found that fNE contains detectable levels of endotoxin (unpublished data). It was
speculated that this novel strain of fungi along with endotoxin in fNE may be responsible
for activating several innate pattern recognition receptors (PRRs), which could be
responsible for its anti-inflammatory, anticancer and other immune-modulating
properties. In this study, we tested DCs treated with fNE, endotoxin-removed fNE (EfNE), or LPS for expression of genes involved with PRR signaling via real-time PCR.
We show for the first time that fermented Noni, the most popular traditional method of
Noni consumption, increases several inflammatory mediators at suppressed levels
compared to LPS, but upon endotoxin removal, clearly promotes an anti-inflammatory
response from DCs.
3.3. Materials and Methods
3.3.1. Animals
Female C57BL/6J mice, 6-8 weeks of age, were purchased from Jackson
Laboratories (Bar Harbor, ME) and housed in our pathogen-free animal facilities.
Animal experiments were carried out in accordance with both Guidelines for the Care
and Use of Laboratory Animals (NIH Publication number 85-23) and institutional
guidelines.
3.3.2. Dendritic Cells
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Bone marrow-derived DCs were cultured as previously described (Lutz et al.,
1999). Briefly, bone marrow cells flushed from C57BL/6J mouse femurs and tibiae with
RPMI-1640 (Gibco BRL) were filtered through 40-µm nylon cell strainers. After lysing
of RBCs with ACK lysing solution, the cell pellet was resuspended in DC medium
containing RPMI-1640 (Gibco BRL) supplemented with 10% FBS (Hyclone), 50 µg/ml
gentamicin (Gibco BRL), and 20 ng/ml rmGM-CSF (Sigma, St. Louis, MO) and plated at
a density of 4-5x106 cells/10 ml in a 100-mm tissue culture dish. On day 4, 10 ml fresh
DC media was added to each dish. On day 8, nonadherent and loosely adherent cells
were harvested, washed with RPMI-1640 and replated into 6-well plates with fresh DC
medium containing 10 ng/ml rmGM-CSF. These DC cultures were stimulated overnight
with either filtered fNE supernatant at 1, 5 or 10% or LPS at 2.5, 12.5, 25 or 100ng/ml
prior to RNA extraction.
3.3.3. Production of Fermented Noni Exudate (fNE)
Production of fNE was previously reported (Zhang et al., 2009). Briefly, ripe
Noni (Morinda citrifolia) fruits were harvested from Kawaihae, Hawaii, thoroughly
cleaned and placed in sterilized containers for fermentation at 24-30°C and humidity
between 45-55%. Fermentation was terminated at 14 days and the seepage was collected
in plastic bottles and stored at -80°C prior to its use. Before incubation with DCs, the
liquid fermented Noni exudate (fNE) was pH adjusted to 7.0-7.4 with 50% NaOH,
centrifuged to discard debris and sterilized by passing through a 0.22µm syringe filter.
Endotoxin removal of Noni was performed by Detoxi-Gel™ Endotoxin Removing Gel
(Thermo Scientific) according to manufacturer’s instructions. Briefly, Detoxi-Gel
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columns were regenerated with 1% sodium deoxycholate, then washed with pyrogen-free
DPBS (Lonza) prior to fNE loading. Once fNE was loaded onto the column, it was
allowed to sit at room temperature for one hour before washing through with an equal
amount of DPBS. The endotoxin-depleted fNE flow-through was collected, passed
through a 0.22µm filter, and used immediately in cell cultures.
3.3.4. Real-Time RT-PCR
Purified total RNA was isolated from stimulated or non-stimulated DCs using the
RNeasy Plus Kit (Qiagen) according to the manufacturer’s protocol and reverse
transcribed with QuantiTect Reverse Transcription Kit (Qiagen). Nucleic acids were
quantified using a Qubit fluorometer and appropriate Quant-it Assay Kits (Invitrogen).
cDNA was analyzed for the expression of Tlr4, Tnf, Il-6, Ptgs2, Ccl3 and Ccl5 by SYBR
green chemistry real-time PCR using the QuantiTect SYBR Green Kit (Qiagen). Realtime RT-PCR was carried out on the Mastercycler ep Realplex2 (Eppendorf) with PCR
cycles recommended by the primer sets. Primer sequences were purchased from Real
Time Primers, LLC and their sequences are available online at
www.realtimeprimers.com.
3.3.5. PCR Array
Purified total RNA was isolated as described above for use in the PCR arrays;
however, it was reverse-transcribed with RT2 First-Strand cDNA Synthesis Kit
(SABiosciences). Manufacturer’s instructions were followed for running the PCRarray;
briefly, cDNA templates were mixed with the provided PCR master mix and were
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aliquoted into all 96-wells of the Toll-like Receptor Signaling Pathway PCRarray
(SABiosciences). The PCR cycling program was set according to the PCRarray protocol.
3.3.6. Statistical Analysis
Fold change in gene expression for real-time RT-PCR data was calculated using
the Pfaffl method, taking into account varying primer efficiencies. Statistical analyses of
data were performed by analysis of variance (ANOVA) followed by Bartlett’s test using
Graph Pad Prism® 4 software. PCR arrays were analyzed with the complimentary RT2
Profiler TM PCR Array Data Analysis (SABiosciences) which determines ∆∆Ct
calculations normalized to at least 3-5 housekeeping genes, with pair-wise comparison
between treated and untreated samples.
3.4. Results
3.4.1. Real-time RT-PCR
Immature DCs (iDCs) were treated with fNE or E-fNE at 1%, 5% or 10% total
media concentration, or LPS at 2.5ng/ml, 12.5ng/ml and 25ng/ml for 2, 24, 48 or 72h.
LPS concentrations were calculated to be equivalent to endotoxin levels of fNE. Total
RNA was extracted and the expression of Tlr4 and five downstream genes of the TLR4
pathway were assessed by real-time RT-PCR using ∆∆Ct method of analysis.
3.4.1.1. Toll-like receptor 4 (tlr4)
fNE did not affect tlr4 gene expression after 2h treatment. At 24 and 48 hours,
5% fNE significantly decreased tlr4, while surprisingly, 10% fNE did not change the
gene expression in these time periods. After 72h treatment, a clear dose-dependent
down-regulation of tlr4 was observed (Figure 3.1A). Since fNE contains LPS (our un-
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published data), we also tested the effect of LPS on tlr4 expression by DCs. LPS in
concentrations equivalent to the amount measured in fNE was used. LPS had no effect
on tlr4 at 2, 48 or 72h. Only at 24h was tlr4 expression significantly downregulated by
12.5 and 25 ng/mL LPS, respectively (Figure 3.1B). Furthermore, since the downregulation of tlr4 gene expression induced by fNE was not completely repeated by LPS
treatment, we tested the effect of endotoxin-removed fNE, or E-fNE, on iDCs. After 24
hours treatment, both 1% and 5% E-fNE significantly downregulated tlr4, while at other
time points (2h, 48, or 72h), there was no effect (Figure 3.1C). These data suggest the
down-regulation of tlr4 gene expression by fNE induced DCs is not completely due to
endotoxin.
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Figure 3.1. tlr4 expression by Noni- or endotoxin-depleted Noni-treated BMDCs
compared to LPS treated BMDCs. BMDCs were treated for 2, 24, 48 or 72h with Noni
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS). Real-time RT-PCR was
performed on cDNA from the resulting samples. (A) fNE treatment of BMDCs; (B) LPS
treatment of BMDCs; (C) E-fNE treatment of BMDCs. Experiments were perfomed in
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05
** p<0.01 *** p<0.001

55

3.4.1.2. Tumor necrosis factor-alpha (tnf)
DCs treated with fNE induced a dose-dependent increase of tnf gene expression at
2h, while at 24h and 48h, only 10% fNE caused a significant increase. At 72h, all three
concentrations induced a significant, albeit small, increase (Figure 3.2A). Similarly, LPS
treatment of DCs caused a strong, non-dose dependent increase in tnf at 2h. At 24h, only
25ng/mL LPS significantly altered the expression of tnf; and by 72h there was no
significant change (Figure 3.2B). E-fNE treatment of DCs, on the other hand, induced a
dose-dependent decrease in tnf expression at 2h. While 24h and 48h incubations did not
cause a significant change, 72h treatment induced a very significant 6.6-fold decrease in
tnf (Figure 3.2C). The increase in tnf by fNE-treated DCs seems to be attributed to the
endotoxin in Noni, since upon endotoxin removal, not only is tnf production abrogated,
but it is actually dose-dependently decreased. This fraction of Noni responsible for
decreasing tnf is also observed in fNE-treated DCs since 5% fNE treatment only caused a
14-fold increase and equivalent endotoxin concentrations (12.5ng/mL LPS) induced 125fold increase in tnf production; therefore there is some inhibition of tnf by Noni.
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Figure 3.2: tnf expression by Noni- or endotoxin-depleted Noni-treated BMDCs
compared to LPS treated BMDCs. BMDCs were treated for 2, 24, 48 or 72h with Noni
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS). Real-time RT-PCR was
performed on cDNA from the resulting samples. (A) fNE treatment of BMDCs; (B) LPS
treatment of BMDCs; (C) E-fNE treatment of BMDCs. Experiments were perfomed in
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05
** p<0.01 *** p<0.001
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3.4.1.3. Interleukin-6 (il-6)
fNE treatment caused a dose-dependent increase in il-6 production by iDCs at 2h;
however, only 10% fNE remained effective through 72h, where its production peaked at
48h, 633.8-fold higher than untreated DCs (Figure 3.3A). LPS treatment also caused a
non dose-dependent increase at 2h, where it peaked at 985.3-fold greater than the control.
Lower dose-dependent responses were noted at 24h and 48h, with a drastic latent rebound
at 72h where 12.5 and 25 ng/mL LPS treatment increased il-6 expression 717- and 731fold above untreated DCs (Figure 3.3B). E-fNE completely abolished the up-regulation
of il-6 induced by fNE. Furthermore, a very significant down-regulation of il-6 occurred
for 1% E-fNE, dropping 47-fold (Figure 3.3C). fNE significantly increased il-6
expression in DCs, although not as high as LPS. Upon endotoxin removal, E-fNE
ultimately decreases production of il-6 at 72h. Again, endotoxin seems to be responsible
for the increase in il-6, while E-fNE actually down-regulates il-6 expression.
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Figure 3.3: il-6 expression by Noni- or endotoxin-depleted Noni-treated BMDCs
compared to LPS treated BMDCs. BMDCs were treated for 2, 24, 48 or 72h with Noni
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS). Real-time RT-PCR was
performed on cDNA from the resulting samples. (A) fNE treatment of BMDCs; (B) LPS
treatment of BMDCs; (C) E-fNE treatment of BMDCs. Experiments were perfomed in
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05
** p<0.01 *** p<0.001
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3.4.1.4. Prostaglandin-endoperoxide synthase 2 (Ptgs2)
Treatment of iDCs with fNE caused a dose-dependent increase in ptgs2 at 2h,
followed by a sustained up-regulation through 48h by 10% fNE. Although a lower fold
increase, 5% and 10% fNE significantly upregulated Ptgs2 expression at 72h (Figure
3.4A). LPS treatment also caused a dose-dependent increase at 2h, followed by an 854fold peak at 24h. Levels decreased by 48h, but remained dose-dependently upregulated.
Surprisingly, at 72h 2.5 ng/mL and 25 ng/mL LPS treatments upregulated ptgs2 635- and
584-fold, respectively, while 12.5ng/ml LPS did not show any effect. Of interest, at 2h
the upper level of concentrations for both fNE and LPS treatments induced a nearly
identical up-regluation of ptgs2 at 453- and 445-fold, correspondingly (Figure 3.4B). EfNE induced a much smaller scale up-regulation of ptgs2, peaking at merely 15.2-fold
above the DC control. At 72h, it began to down-regulate expression, where 1% E-fNE
decreased ptgs2 19-fold (Figure 3.4C). It is likely that some other component of fNE is
responsible for up-regulating the production of ptgs2, since upon endotoxin removal, 2h
treatment with E-fNE still induces a dose-dependent up-regulation, although a transient
effect.
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Figure 3.4: ptgs2 expression by Noni- or endotoxin-depleted Noni-treated BMDCs
compared to LPS treated BMDCs. BMDCs were treated for 2, 24, 48 or 72h with Noni
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS). Real-time RT-PCR was
performed on cDNA from the resulting samples. (A) fNE treatment of BMDCs; (B) LPS
treatment of BMDCs; (C) E-fNE treatment of BMDCs. Experiments were perfomed in
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05
** p<0.01 *** p<0.001
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3.4.1.5. Chemokine ligand-3 (Ccl3)
At 2h, ccl3 expression peaked with 5% fNE treatment. At 24h, 1% and 5% fNE
did not significantly alter its expression, but 10% fNE induced the highest level of ccl3 at
8.13-fold above control. By 48h, 1% and 5% fNE significantly downregulated ccl3
(Figure 3.5A). LPS induced stronger ccl3 expression at 2h than fNE, peaking at 26-fold
above control for 12.5 ng/mL; however, no significant change occurred from 24-72h
(Figure 3.5B). E-fNE abolished the effects of ccl3 up-regulation by fNE and strongly
downregulated its expression at 72h, where 1% E-fNE decreased ccl3 expression as low
as 27.5-fold below control (Figure 3.5C). Overall, fNE and LPS treatment quickly
increased expression of ccl3 in DCs, but this effect tapered off with time. Upon removal
of endotoxin, E-fNE caused no significant change in ccl3 expression from 2-48h, but a
strong 27.5-fold down-regulation at 72h. Endotoxin appears responsible for ccl3
expression by fNE-treated DCs.
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Figure 3.5: ccl3 expression by Noni- or endotoxin-depleted Noni-treated BMDCs
compared to LPS treated BMDCs. BMDCs were treated for 2, 24, 48 or 72h with Noni
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS). Real-time RT-PCR was
performed on cDNA from the resulting samples. (A) fNE treatment of BMDCs; (B) LPS
treatment of BMDCs; (C) E-fNE treatment of BMDCs. Experiments were perfomed in
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05
** p<0.01 *** p<0.001
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3.4.1.6. Chemokine ligand-5 (Ccl5)
fNE treatment caused no significant change in ccl5 production at 2h, but a dosedependent increase was observed at 24h, 48h and 72h. Its production peaked at 72h for
10% fNE, where it was 62.5-fold higher than untreated DCs (Figure 3.6A). LPS at
12.5ng/ml and 25ng/ml induced minimal expression of ccl5 at 2h, then a much greater
expression from 24-72h, peaking at 78.4-fold at 24h. Ccl3 production remained
increased at relatively consistent levels for all concentrations of LPS from 24-72h (Figure
3.6B). E-fNE caused no significant change in ccl3 expression from 2-48h, but again,
induced down-regulation of the gene at 72h, where 1% E-fNE caused a 19.7-fold
decrease, and 5% caused a 7.46-fold decrease (Figure 3.6C).
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Figure 3.6: ccl5 expression by Noni- or endotoxin-depleted Noni-treated BMDCs
compared to LPS treated BMDCs. BMDCs were treated for 2, 24, 48 or 72h with Noni
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS). Real-time RT-PCR was
performed on cDNA from the resulting samples. (A) fNE treatment of BMDCs; (B) LPS
treatment of BMDCs; (C) E-fNE treatment of BMDCs. Experiments were perfomed in
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05
** p<0.01 *** p<0.001
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3.4.2. RT-PCR Array
Based on the greater suppressive nature of E-fNE, we decided to further examine
some other genes involved in signaling pathways and adaptor molecules affected by EfNE. We performed real-time PCR array on 84 genes involved in TLR signaling and
several downstream pathways (NFκB, JNK, IRF, etc). iDCs were incubated with 5% EfNE for 2, 24 or 48h; total RNA was extracted, and real-time RT-PCR was performed to
assess the regulation of genes related to TLR signaling. Upregulated and downregulated
genes, compared to non-stimulated DC controls, are represented in Table 3.1 and Table
3.2, respectively.
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Upregulated Genes (Fold Regulation)
Gene

2 hour

p

Tlr2

2.7

***

Tlr5

2.3

*

Cd14

1.7

**

Hspa1a

2.1

**

Mapk8ip3

1.7

*

Peli1

2.7

***

Ripk2

2.3

*

Tollip
Traf6

2.6

Ifnβ1

10.5

24 hour

p

32.8

***

1.6

**

48 hour

560.3

*
***

157.8

***

1596

Il-1a

16.6

***

Il-1b

28.3

***

Il-6

41.9

***

36.8

***

47.2

Il-10

18.7

***

15.7

***

1.6

Nfkb1

2

Nfkb2

1.8

***

**

Nfkbia

3.2

***

Nfkbib

2.7
1.8

*

2.3

*

Nfkbil1

3.1

***

Rel

4.7

***

Tnfaip3

5.3

**

Jun

1.5

*

Mapk8

1.8

*

Clec4e

3.4

**

Ptgs2

83

***

267.8

Cxcl10

15.8

***

6

Ifnβ1

157.8

Cebpb

2
2

10.5

***

Irf1

2.3

**

Irf3

1.9

**

Tbk1

1.7

Cd80

2.5

Cd86

4

**

***

2.4

*

47.2

***

1596
2.3

2.5

*

6.6

3.7

**

3.3
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Table 3.1: Upregulated genes of the
TLR signaling pathway by Noni
treated DCs. Non-stimulated BMDCs
were treated with 5% endotoxinremoved fermented Noni exudate (EfNE) for 2, 24 or 48h. Total RNA was
extracted and real-time RT-PCR was
performed on the 84 genes of the TLR
pathway PCRarray from
SABiosciences. Arrays were
normalized to at least 2-5
housekeeping genes and compared to
non-treated BMDCs. Triplitate
PCRarrays were performed on 2h and
24h samples. Only one PCRarray was
performed on the 48h E-fNE sample
and one on the 48h non-treated DC
control. The delta-delta Ct method
was used to calculate fold change in
gene expression.

Downregulated Genes (Fold Regulation)
Gene

2 hour

p

24 hour

p

Tlr1

-2.6

*

Tlr2

-4.2

***

Tlr4

-5.3

**

Tlr5

48 hour
-2.3
-15.2
-10.6

Tlr7

-8.6

*

-4.2

Tlr8

-299

***

-228

Tlr9

-5.5

**

-6.7

Btk

-6.0

***

-5.3

Cd14

-9.1

Ly86

-22.8

***

Ly96

-3.4

Myd88

-5.2

***

Peli1

-9.5
-2.4

Ticam2
Tirap

-18.6

-3
-2.4

**

*

-6.5
-13.9

Casp8

-3.8

***

-10.3

Fadd

-3.1

**

-7.4

Irak1

-9.6

*

-3.5

Map3k7

-2.9

***

-4.3

Ube2n

-6.9

***

Ube2v1
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**

Ccl2

-2.2

***

-38.3

Ikbkb
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**

-10.6

Il-1a

-10.8

Il-1b

-76.6

Il-1r1
Map3k1
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**

-2.7

*

Rela

-10.3

*

Tnf

-15.4

*

Tnfrsf1a

-3.5

**

Elk1

-2.4

*

Fos

-5.9

**

Map2k3

-3.6

***

Map2k4

-2.5

*

Map3k1

-2.8

*

Map3k7
Mapk9
Il-6ra

-8.9

-3.4
-9.6
-2
-4.7
-4.3

-4
-7.6

***

-6.5

**

-234

68

Table 3.2: Downregulated genes of
the TLR signaling pathway by Noni
treated DCs. Non-stimulated BMDCs
were treated with 5% endotoxinremoved fermented Noni exudate (EfNE) for 2, 24 or 48h. Total RNA was
extracted and real-time RT-PCR was
performed on the 84 genes of the TLR
pathway PCRarray from
SABiosciences. Arrays were
normalized to at least 2-5
housekeeping genes and compared to
non-treated BMDCs. Triplicate
PCRarrays were performed on 2h and
24h samples. Only one PCRarray was
performed on the 48h E-fNE sample
and one on the 48h non-treated DC
control. The delta-delta Ct method
was used to calculate fold change in
gene expression. Fold regulation
gives magnitude and direction of
regulated genes.

3.4.2.1. Toll-like receptors (TLRs)
Bone marrow-derived DCs expressed higher levels of genes for TLRs 2,4,8 and 9
than TLRs 1,5 and 7; however, tlr3 was not expressed. Tlr2 and tlr5 were upregulated
upon E-fNE stimulation after 2h. Then at 24h, tlr(1,2,4,7,8,9) were all downregulated
with tlr8 showing a striking 299-fold decrease. At 48h, tlr(1,2,5,7,8,9) all decreased with
tlr8 at 228-fold below untreated DCs.
3.4.2.2. TLR adaptors and interacting proteins
At 2h, several adaptor molecules commonly associated with TLR2 were
upregulated (ripk2, cd14, hspa1a) (Zhang et al., 2009); while tirap and ly96 (MD2),
which are commonly associated with TLR4, were downregulated.
By 24h, only hspa1a remained upregulated, and was joined by tollip, known to diminish
TLR2 and TLR4 responses in mammals. Many other adaptors were downregulated (ly86
(MD1), btk, myd88, tirap, and ticam2). These genes were still downregulated at 48h and
were joined by cd14 and ly96. Hspa1a on the other hand, exponentially increased 560fold.
3.4.2.3. Cytoplasmic effectors
The only upregulated gene in the effector group was traf6, which was upregulated
at 2h. And by 24h, most effectors were downregulated including casp8, fadd, irak1,
map3k7, eif2ak2, ube2v1 and ube2n. At 48h, casp8, fadd, irak1, map3k7, and eif2ak2
remain decreased.
3.4.2.4. NFκ
κB pathway and target genes
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At 2h, nfkb1 and nfkb2 were upregulated by E-fNE treated DCs, along with the
inhibitors, nfkbia, nfkbib, nfkbil1, and tnfaip3. Expression of cytokines il-6, il-1a, il-1b,
il-10 and ifnβ1 were also increased at 2h. Ccl2 was the only gene significantly
downregulated at 2h.
By 24h, ifnβ1 increased 158-fold compared to untreated DCs, and nfkbib, il-6, il10, and rel expression remained upregulated. Downregulated genes include tnf (15.4-fold
reduction), il-1r1, ikbkb (IKK-β), tnfrsf1a, and map3k1 (MEKK-1).
The only cytokines remaining increased at 48h include ifnβ1, which exponentially
increased 1596-fold above untreated DCs, and il-6, which remained steady. Tnfaip3 and
nfkbia inhibitors were also upregulated at 48h. Several cytokines were downregulated
(il-1a, il-1b, ccl2) along with ikbkb (IKK-β), il-1r1 and tnfrsf1a.
3.4.2.5. JNK/p38 pathway
E-fNE treatment of DCs resulted in increased mapk8 (JNK1) and jun expression
by 2h. By 24h, jun remained upregulated, but most of the p38 pathway genes were
downregulated including, mapk9 (JNK2), map2k3 (MKK-3), map2k4 (MKK-4), map3k1
(MEKK-1), elk1 and fos). All but map3k1 and elk1 remained downregulated at 48h, but
were replaced by map3k7.
3.4.2.6. NF/IL-6 pathway
The NF/IL-6 transcription factor is responsible for stimulating the promoter
region of the COX-2 (ptgs2) gene. Ptgs2 had the largest increase at 2h and 24h for all
genes in this pathway (83- and 268-fold, correspondingly). Clec4e and cebpb (CRP2)
were increased at 2 and 24h, respectively. And only ptgs2 remained upregulated at 48h.
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Il-6ra, on the other hand, was the only gene downregulated in this pathway with a 7.6fold decrease at 24h and 234-fold at 48h.
3.4.2.7. Co-stimulatory markers
The gene for cd80 was minimally increased at 2h, and both cd80 and cd86 were
slightly induced from 24-48h.
3.4.3. FACS Analysis
When treating DCs with Noni, we observed a striking difference in cell adherence as well
as the monolayer morphology compared to untreated DCs and DCs treated with LPS.
These Noni-treated cells became very sticky even after only 2h treatment, and in most
instances, cell scraping was required to collect enough cells for further experiments. This
prompted further investigation to determine the phenotype of the cell population used in
these studies. Non-stimulated DCs were harvested after 7 days of culture, resuspended in
DC media and treated for 24h with fNE, E-fNE, LPS, E-fNE plus simultaneous addition
of LPS, or LPS for 24h then fNE or E-fNE for an additional 24h. Fluorescent-labeled
antibody staining was performed and analysis was carried out on the FACS Caliber. The
results were confirmed in duplicate or triplicate runs.
3.4.3.1. Fermented Noni exudate (fNE)
Around 85% of the cells from all treatments were CD11c+. DCs treated with fNE
minimally increased CD11c+Mac-3+ cells by 6%, and a small increase was seen in the
CD11c+CD62L+ population, compared to both DC and LPS controls (Figure 3.7).
However, CD83 expression doubled, similar to the LPS control, and CD40 expression
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quadrupled, although remaining 20% lower than LPS stimulated DCs. The
CD11c+Gr1+B220+ population nearly doubled, but was similar to the LPS control.
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Figure 3.7: Surface marker expression of dendritic cells treated with Noni or
Entotoxin-depleted Noni compared to LPS. BMDCs were treated with 5%
Noni, 5% endotoxin-depleted Noni or 100ng/ml LPS for 24h, then stained with
corresponding FITC- or PE-conjugated antibodies. (A) Non-stimulated CD11c+
BMDCs expressed low levels of CD83, Mac-3, CD62L and CD40. (B) Noni
treated cells expressed slightly elevated levels of CD83, Mac-3, and CD62L, but a
large increase in CD40. (C) Endotoxin-depleted Noni stimulated a large increase
in Mac-3 and CD62L with only a moderate increase in CD40, and no change in
CD83. (D) LPS stimulated the largest increase in CD83 and CD40, however
there was no change in Mac-3, and a minimal increase in CD62L. All
experiments were perfomed in duplicate or triplicate to confirm the resulting
patterns.
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3.4.3.2. Entotoxin-depleted fermented Noni exudate (E-fNE)
This visual phenomenon was observed for both fNE and endotoxin-removed fNE,
so we examined the surface phenotype of E-fNE-treated DCs as well. An even larger
proportion became CD11c+Mac-3+, a striking 66% of the total cell population. And the
CD62L+ cells increased from 1.5% in the DC control (4% in the LPS control) to 30%
(Figure 3.7). CD11c+CD83+ cells remained the same after treatment with E-fNE;
however, CD40 expression doubled. The CD11c+Gr1+B220+ population nearly doubled
compared to the LPS control. Interestingly, E-fNE-treated cells slightly increased
expression of MHC class I molecule.
3.4.3.3. E-fNE with LPS (E-fNE + LPS)
To determine if endotoxin removal was responsible for the large increase in
Mac3+ or CD62L+ cells, and to assess its requirement for CD40 stimulation, we incubated
DCs simultaneously with E-fNE and LPS for 24h. This appeared to have no effect on
Mac-3+ cells, and a very mild effect on CD62L+ cells; however, CD40 expression was
increased to nearly that of LPS treated cells (Figure 3.8). Hence, LPS is necessary for
induction of CD40, but it does not significantly hinder the E-fNE induced differentiation
to Mac-3+ and CD62L+ cells.
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Figure 3.8: Surface marker expression of dendritic cells treated with Noni or
Endotoxin-depleted Noni and simultaneous addition of LPS. BMDCs were
treated with 5% Noni or 5% endotoxin-depleted Noni along with 100ng/ml LPS for
24h, then stained with corresponding FITC- or PE-conjugated antibodies. The
addition of LPS was not sufficient to block the transformation to Mac-3+ cells in
endotoxin-depleded Noni stimulated DCs. Although, it significantly increased
expression of CD40 for both Noni and endotoxin-depleted Noni samples.
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3.4.3.4. fNE post-LPS
Since immature DCs are known to have a high degree of plasticity, we decided to
mature DCs with LPS for 24h, followed by a 24h fNE treatment to determine the strength
of Noni’s effect on matured DCs. Indeed, maturation of DCs with LPS was not sufficient
in blocking the differentiation of DCs to Mac-3+ or CD62L+ cells by fNE, nor did it alter
the expression of CD83+ cells (Figure 3.9). The only marker affected by LPS treatment
prior to fNE treatment was CD40. Its expression increased to levels similar to the LPS
control.
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Figure 3.9: Surface marker expression of dendritic cells treated with Noni or
Entotoxin-depleted Noni, pre-treated with LPS. BMDCs were treated with
100ng/ml LPS for 24h, then subsequently with 5% Noni or 5% endotoxin-depleted
Noni for an additional 24h, and stained with corresponding FITC- or PE-conjugated
antibodies. Pre-treatment of DCs with LPS was not sufficient to block the
development of Mac-3+ cells for endotoxin-depleted Noni-treated DCs, and in fact,
appeared to augment the expression of Mac-3 for Noni-treated DCs. LPS was
responsible for the large increase in CD40.
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3.4.3.5. E-fNE post-LPS
LPS pre-treatment did not hamper the ability of E-fNE to increase Mac-3+ or
CD62L+ cells either. In fact, Mac-3+ cells actually increased compared to E-fNE treated
DCs alone. CD83 and MHC-I expression remained unchanged compared to fNE
treatment; however, the CD11c+Gr1+B220+ population minimally increased to its highest,
35% of the total cell population. Again, CD40 expression was increased to levels near
that of the LPS control, which were much higher than E-fNE-treated cells.
Here we show that LPS-matured DCs are not terminally differentiated, as they are
affected by fNE or E-fNE treatment to trans-differentiate from CD11c+CD83hiMac-3lo
population to CD11c+CD83loMac-3hi population with an increasing population of
CD11c+Gr1+B220+ cells.
3.5. Discussion
Overall BMDC treatment with Noni muted the level of inflammatory signaling compared
to proportionate levels of LPS. By removing endotoxin from Noni (E-fNE), there was a
shift from an early mild inflammatory response in BMDCs followed by a time-dependent
increase in anti-inflammatory mediators. Endotoxin removal of Noni not only
encumbered expression of tnf, il-6, ptgs2, ccl3, and ccl5 initiated by fNE, but actually
caused a decrease in their expression by at least 72h. This arrest of inflammatory factors
was confirmed with real-time PCR arrays and revealed the eventual switch to antiinflammatory mediators with time.
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3.5.1. fNE and E-fNE decrease inflammatory mediators
In our experiments, fNE caused a decrease in tnf, il-6, ptgs2, ccl3 and ccl5
compared to LPS controls, and upon removal of endotoxin, this decrease was even more
evident. It is possible this is achieved simply through a unique combination of pattern
recognition receptor (PRR) signaling brought about by the plethora of microbial
degradation compounds within fNE. Many microorganisms have been cultured from
non-pasteurized Noni juice, including E. coli; however, upon fermentation there remains
only one surviving microbe (personal communication). This plethora of microbial byproducts may induce a combination of receptors to limit production of genes involved
with inflammation.
Some of the most popular traditional uses of Noni targeted inflammation, where it
was often applied topically to treat arthritis, inflammation due to sprains or broken bones,
general pains, and even taken internally to treat asthma (Wang et al., 2002) (Pawlus et
al., 2007). With its resurgence in popularity as an herbal tonic, more research has been
conducted to identify components of Noni responsible for these effects. Constituents of
Noni fruit have previously been implicated in reducing inflammatory cytokines and
inhibiting 5-lipoxygenase activity (Wang et al., 2002) (Deng et al., 2007). Furthermore,
Hiruzimi and Furusawa demonstrated that fermented Noni-ppt induced macrophage cells
to produce lower levels of TNF-α and IL-1b than LPS-induced cells; and IL-10
production was consistent between the two groups. These Noni-induced macrophage
cells were also responsible for the enhanced survival of mice with LLC tumors (Hirazumi
et al., 1999). Our results similarly show that tnf is produced at much lower levels than
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LPS stimulated BMDCs (Figure 3.1), and by 24h it is actually downregulated (tnf levels
are below control levels); and il-1a and il-1b were stimulated early (Table 3.1) but by 48h
were also below control levels (Table 3.2). More recently, Palu et al reported Tahitian
Noni Juice precipitate was shown to activate cannabinoid receptors, specifically CB2
(Palu et al., 2008). This receptor is found mainly in T cells, macrophages and B cells, as
well as other hematopoietic cells and is responsible for mediating protective signals
against inflammatory responses (Massa etl al., 2004). It has also been found that
Echinacea and several other botanicals activate CB2 receptors (Raduner et al., 2006;
Woelkart et al., 2008). These data support our findings that Noni-stimulated BMDCs
decrease inflammatory mediators. One mechanism of action may be their ability to
activate CB2 receptors.
3.5.2. Endotoxin-depleted Noni up-regulates anti-inflammatory mediators
Noni was observed not only to down-regulate inflammatory cytokines, but also to
up-regulate anti-inflammatory mediators. With time, endotoxin-removed Noni increased
levels of anti-inflammatory mediators in BMDCs such as ifnβ1 and hspa1a (Table 3.1),
while concomitantly decreasing inflammatory mediators (Table 3.2). Both IFN-β and
HSP70 are implicated in treating chronic inflammatory maladies (Musch et al., 2007;
Olofsson et al., 2007; Corr et al., 2009; Tao et al., 2009; Tanaka et al., 2007) (Pockley et
al., 2008). Type I IFNs are capable of anti-proliferative effects and often mediate
hematopoietic suppressive signals (Platanias et al., 2005). It has been shown that Type I
IFNs increase NK cell activity, enhance phagocytic abilities of APCs, and promote
cytotoxic properties of stimulated lymphocytes (Borden et al., 1998) (Sato et al., 2001).
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HSP70 was also demonstrated to activate NK cells (Multhoff et al., 1997; Gross et al.,
2003) via TLR2 and TLR4 (Asea et al., 2002). Recently, Li and colleagues reported the
necessity of NK cells and T cells for the tumor killing and preventative properties of
Noni (Li et al., 2008). Similarly, Furusawa et al attributed the anticancer properties of
Noni-ppt to macrophages, NK cells and T cells (Furusawa et al., 2003). Our data,
revealing Noni-induced BMDCs increase production of ifnb1 and hspa1a, may shed light
on the anti-cancer mechanisms of Noni observed by these studies.
Besides its NK-activating effects, HSP70 has been implicated as an anti-apoptotic
and anti-inflammatory mediator (Hall et al., 1994) (Yenari et al., 2005) and there are
several studies involving its use as an adjuvant for cancer therapies (Zhang et al., 2007i;
Kumar et al., 2009; Wu et al., 2005). Recently it has been implicated in the protection
from inflammatory-drug induced colon cancer in a mouse model for inflammatory bowel
disease cancer (Tao et al., 2009). On a mechanistic level, HSP induction inhibits proinflammatory cytokines by inhibiting NFκB. This inhibition is through the stabilization
of IkB; however the exact mechanism is still not clear (Yoo et al., 2000; Schell et al.,
2005). Hspa1a levels increase drastically with time in endotoxin-removed Noni-treated
DCs (Table 3.1), which may be partially responsible for the latent commitment to antiinflammation. Since IkBa (nfkbia) levels are increased at 2 and 24h (Table 3.1), HSP70
may be essential for their stability and suppression of NFκB inflammatory responses. It
was recently reported that the anti-inflammatory effects of HSP70 were critically
dependent on IL-10 (Wieten et al., 2009). And our data revealed il-10 gene expression
was also elevated in BMDCs treated with endotoxin-removed Noni. Noni induction of
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hspa1as a role in the inhibition of NFκB-mediated inflammation should be further
investigated. The involvement of HSP70 in the stabilization of IkB and subsequent
inhibition of NFκB should be examined.
3.5.3. E-fNE inhibition of NFκ
κB
There has been long standing evidence for the association of inflammation and
cancer, and NFκB transcription factors are responsible for the production of many
inflammatory genes. TNF-α, IL-1 and IL-6 are programmed by the classical NFκB
pathway and are associated with cancer progression (Karin et al., 2005). IL-6 in
particular is associated with unfavorable prognosis in breast cancer recurrence (Zhang et
al., 1999). These inflammatory mediators are hijacked by the tumor microenvironment
to their own advantage, recruiting innate immune cells such as TAMs (tumor associated
macrophages), tolerogenic DCs and regulatory T-cells to perpetuate this inflammatory
environment, allowing for angiogenesis and metastasis. In congruence with the negative
association of inflammation and cancer progression, long-term use of NSAIDs (nonsteroidal anti-inflammatories), both manufactured drugs and natural remedies, have been
linked to reduced incidence of certain inflammation-associated cancers (Jacobs et al.,
2005; Fairfield et al., 2002; Corley et al., 2003). NSAIDs and botanicals such as green
tea, resveratrol and curcumin all have been shown to inhibit NFκB (Siddiqui et al., 2008;
Majumdar et al., 2009; Aggarwal et al., 2004; Aggarwal et al., 2003). Our results show
that although fNE induces cytokine gene expression, its levels of tnf, il-1 and il-6 are
much lower than LPS. Noni’s immunomodulatory properties may regulate the immune
system in a way that favors anti-tumor activity via inhibition of NFκB.
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Our data show a clear trend in NFκB inhibition by E-fNE. Not only are NFκB
inhibitors (nfkbia, nfkbib, nfkbil1, tollip, tnfaip3) increased, but ikbkb (IKK-β) is
significantly downregulated. Tollip is an inhibitor of IRAK-1 activation, however, once
TLR ligands are recognized and TLRs dimerize, Tollip is released and IRAK-4 is capable
of activating IRAK-1 (Figure 3.10). Pellino is recruited with TRAF-6 to form a
membrane complex (II) with TAB/TAK, then it causes poly-ubiquitination with
subsequent degradation of IRAK-1, releasing Complex III into the cytosol. TAK1 then
activates IKKs and MKKs. IKK-β is responsible for phosphorylating IκB and thus
releasing NFκB dimers to enter the nucleus. As seen in Tables 1 and 2, many of these
NFκB cascade genes are downregulated. This NFκB inhibition could be one explanation
for anti-tumor and antiangiogenic properties of Noni, by limiting inflammatory immune
cell proliferation and lifting the suppression of apoptosis. This may also explain why
Noni enhances the effectiveness of certain chemotherapies.
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Figure 3.10: Toll-like receptor signaling cascade. Upon engagement of TLR ligand,
receptors dimerize. This dimerization brings their cytoplasmic tails together where TIR
domains can interact. IRAK4 and IRAK1 are brought together and IRAK4
phosphorylates IRAK1, allowing for the release of Tollip and its activation. Once
IRAK1 is activated, it is released from the receptor tail and binds to the TAK/TAB
membrane-bound complex. Pellino1 is a scaffold protein responsible for bringing TRAF6
to the IRAK1/TAK/TAB complex. Pellino ubiquitinates IRAK1, allowing for its
proteasomal degradation and subsequent release of the TAK/TAB/TRAF6 complex.
Upon complex formation, TAK1 is activated and phosphorylates IKKs, which in turn
phosphorylate IκBs. Phosphorylated IκBs are targeted for proteasomal degradation,
which releases the NFκB subunits and allows for their nuclear transmigration. Activated
TAK can also phosphorylate MKKs, which can then activate the p38 and JNK pathways.
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Experiments performed by Kawamur and colleagues presented antithetical
properties of Agaricus blazei-treated BMDCs similar to the results we observed with
Noni-treated BMDCs. A. blazei, an edible mushroom often consumed for purported
health benefits, activated DC maturation with respect to co-stimulatory and MHC
molecules; however, inflammatory cytokine production was reduced when DCs were
treated with A. blazei prior to LPS. This phenomenon was related to its capacity to
inhibit NFκB. Interestingly, A. blazei-treated DCs, although suppressing TH1 cytokines
(IL-12p40), increased TH1 cell development and subsequent IFN-γ production in an
allogenic mixed lymphocyte reaction assay (Kawamura et al., 2005). These results are
similar to what we have observed with Noni-treated BMDCs and again point to the
inhibition of NFκB as a major mechanism of immunomodulation.
3.5.4. Cell surface expression of Noni-treated BMDCs.
Interestingly, we observed a strange phenomenon with the morphology and cell
adhesiveness of Noni-treated BMDCs. The underlying supportive monolayer in the
cultured bone marrow cells became elongated and much denser than in LPS or untreated
bone marrow cell cultures. When trying to collect these cells, they were much more
difficult to harvest than typical non-stimulated BMDCs or even LPS-stimulated BMDCs.
After staining for several bone marrow-derived cell markers, we learned that our Nonitreated cell population had an increasing amount of Mac-3+ cells. This effect was most
prominent in endotoxin-removed Noni-treated BMDCs. Simultaneous stimulation of
BMDCs with endotoxin-removed Noni and LPS did not abrogate this differentiation to
Mac-3+ cells, but in fact slightly enhanced it. Since non-stimulated BMDCs are known to
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be very plastic, we then incubated the cells with LPS for 24h prior to endotoxin-removed
Noni treatment, but observed a nearly identical level of Mac-3+ cells as the original
endotoxin-removed Noni-treated BMDCs. The treatment groups highly positive for
Mac-3 also had a large increase in CD62L+ cells. Is it possible that endotoxin-removed
Noni is capable of transforming DCs into CD62L+ monocytes and allowing for their
subsequent differentiation into Mac-3+ cells? This marvel encourages more research to
determine a more precise phenotype of these purported macrophage cells and to elicit the
pathway by which Noni influences matured DCs to become macrophage-like cells.
3.6. Conclusion
With this study we hope to shed light on some of the anti-inflammatory and
anticancer mechanisms of Noni, in order to better understand this product that has held
long-standing native use for the treatment of many ailments and is receiving a resurgence
in popularity with the advent of Tahitian Noni ® and its approval by the European Food
and Safety Authority (European Food Safety Authority, 2009). Noni elicits an early mild
inflammatory response in BMDCs, followed by an anti-inflammatory response triggered
by high levels of ifnβ1 and hspa1a production and NFκB inhibitors. This divergent
occurrence of pro- and anti-inflammatory mediators may give a unique rise to TH1
immunity while quenching the undesirable effects of prolonged inflammation. It also
causes trans-differentiation of BMDCs into macrophage-like cells expressing Mac-3.
Further research is needed to determine whether these anti-inflammatory mediators are
indeed players in the anticancer effects of Noni. And further investigation into the
known and unknown NFκB inhibitory compounds in Noni would be of great value.
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SUMMARY
Since their discovery as mediators of innate and adaptive immunity, dendritic
cells have been fervently researched. Their ability to enhance innate mediators such as
NK cells, as well as process and present antigen to lymphocytes has led to their use in
many immunotherapies. Scientists have put great effort into understanding their complex
nature in order to harness their power for enhancing or even distinguishing immune
responses. In this study, we have examined DCs in two different settings. First, we
observed the influence of fusion with tumor cells; and second, we tested the effects of
Morinda citrifolia on DCs.
In the first experiment, either immature or mature DCs were chemically fused
with tumor cells and their expression of inflammatory chemokine (CCL), chemokine
receptors (CCRs), and several other DC markers was evaluated. In immature DCs, fusion
induced maturation with respect to CCLs, CCRs, and typical DC maturation markers;
however, mature DCs used for fusion, which already expressed the aforementioned
markers prior to fusion, proceeded to down-regulate CCLs, CCRs, and other markers of
maturation. This peculiar phenomenon of ‘de-maturation’ of DCs clarifies the need for
immature DCs utilized in tumor fusion procedures. This is essential in order to have the
most effective DC-tumor hybridoma vaccine capable of migration to secondary lymph
tissues where they will be most effective at eliciting cell-mediated responses against DC
presented tumor antigens.
The second experiment was aimed at expanding the knowledge of Noni as an
immunomodulator. Noni’s popularity as a dietary supplement and immune enhancer is
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growing, and it is important to understand the mechanisms behind its purported actions.
It is a known activator of DCs, and consists of a wide variety of PAMPs from killed
microflora after fermentation. So, we tested the ability of Noni to activate DCs via TLRs.
By analyzing genes in the TLR signaling pathway via real-time RT-PCR, we observed
that Noni stimulated production of anti-inflammatory mediators as well as inhibiting
pathways downstream of TLRs, including NFκB. And an interesting find was that Nonitreated DCs may actually have trans-differentiated into macrophage cells.
Overall, DCs were shown to be activated by fusion to tumor cells and treatment
with Noni. Further experiments to confirm these findings at the protein level would be
advantageous. Chemotactic assays would benefit the first experiment. And further
investigation of the Noni-induced trans-differentiation of DCs into macrophages would
be of great interest. Lastly, since NFκB inhibitors are generating much attention with
respect to anti-inflammation and anticancer therapies, the role of Noni and NFκB
inhibition may lead to novel drug discoveries.
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